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1. Zusammenfassung 
 
Bei Plattenepithelkarzinom der Haut (SCC) handelt es sich um den zweithäufigsten Hautkrebs 
innerhalb der kaukasischen Bevölkerung. Die Inzidenz dieser Krebserkrankung ist in den 
letzten Jahrzehnten konstant angestiegen und ist zurzeit, auf Grund dessen nicht zu 
unterschätzenden Hang zur Metastasierung, für ein Viertel aller hautkrebsassoziierten 
Todesfälle weltweit verantwortlich. Chronische Sonnenexposition wird als Hauptursache für 
die SCC Entstehung gesehen. Der darin enthaltene Anteil an UV-Strahlung schädigt die DNA 
der Keratinozyten direkt und hinterlässt charakteristische Spuren, die in weiterer Folge zur 
krebsfördernden DNA Mutationen führen können. In den meisten Fällen ist die zelleigene DNA 
Reparaturmaschinerie jedoch in der Lage diese Punktmutationen zu beheben, was den 
Fortbestand der betroffenen Zelle ermöglicht. Im Falle eines irreparablen Genoms wird der 
Keratinozyt die sogenannte Differenzierungskaskade, eine spezielle Form des kontrollierten 
Zelltods, einleiten und sich somit unschädlich machen. Während dieses Prozesses wandern 
die Keratinozyten kontinuierlich Richtung Hautoberfläche, verändern dabei ihre Erscheinung, 
beenden ihre metabolische Aktivität und sterben. Während dieses Prozesses und sogar nach 
dem Zelltod erfüllen differenzierende Keratinozyten wichtige funktionelle Aufgaben wie zum 
Beispiel eine physikalische Abschirmung gegen Umwelteinflüsse und Bakterienangriffe gegen 
den Organismus. 
Falls es einem entarteten Keratinozyten gelingt, sowohl der DNA Reparatur als auch der 
vorzeitigen Differenzierung zu entkommen, stellt das Immunsystem die letzte Hoffnung dar, 
in dem es die gefährliche Zelle erkennt und neutralisiert. Aus diesem Grund haben 
Transplantatempfänger (OTR), unter Immunsuppression, ein erheblich erhöhtes Risiko, auch 
schwere Formen von SCC zu entwickeln. Normalerweise werden SCC operativ entfernt, was in 
den meisten Fällen eine kurative Behandlung darstellt. Ein kleiner Anteil invasiver SCC findet 
den Weg zu Blut- oder Lymphgefässen und breitet sich als metastasierendes SCC in weitere 
Organe des menschlichen Körpers aus. Die Überlebenschancen bei dieser besonders 
aggressiven Form des SCC sind sehr gering und die Behandlungsmöglichkeiten sehr 
beschränkt. Detaillierte Kenntnis über die molekularen Vorgänge während dieser invasiven 
Prozesse sind unerlässlich, um der betroffenen Patientengruppe in Zukunft bessere Therapien 
in Aussicht stellen zu können. 
Physiologische und pathologische Prozesse werden nicht nur durch unterschiedliche 
Expression von proteinkodierenden Genen reguliert, sondern auch durch alternierende 
microRNA (miRNA) Spiegel. miRNAs sind kleine, nichtkodierende, ungefähr 22 Nukleotide 
lange RNA Fragmente, die mit der 3’UTR von mRNAs interagieren und somit deren 
Stabilität/Funktionalität negativ beeinflussen. Aufgrund unterschiedlicher miRNA 
Expressionsmuster mit den einhergehenden Funktionen im Krebs- und normalen Gewebe, 
erscheint eine Einteilung in krebsfördernde (sogenannte Oncomirs) und 
tumorsupprimierende miRNAs sinnvoll. miRNAs sind massgeblich an sämtlichen funktionalen 
Vorgängen in Krebserkrankungen, wie zum Beispiel Proliferation, Apoptose, Bildung von 
Metastasen sowie der Angiogenese, beteiligt. 
Basierend auf unserer Erkenntnis, dass microRNA-181a (miR-181a) eine deutlich reduzierte 
Expression im SCC im Vergleich zur normalen Haut aufweist, habe ich mich in dieser 
Doktorarbeit hauptsächlich mit deren tumorsupprimierenden Rolle bei SCC beschäftigt. Dabei 
provozierte das Fehlen von miR-181a, mittels «knock-down», krebsähnliche Vorgänge wie 
erhöhte Proliferation und gestörte Differenzierung in normaler Haut. Umgekehrt hatte die 
Wiederherstellung der miR-181a Expression in SCC eine Verlangsamung der Zellproliferation 
sowie die Einleitung der Apoptose zur Folge. Unseren Erkenntnissen zufolge ist das Proto-
Onkogen KRAS ein direktes Ziel von miR-181a und befindet sich unter deren Kontrolle in 
Keratinozyten. In unseren Experimenten konnten wir das onkogene Potential von KRAS in SCC 
verdeutlichen, welches durch den MAPK Signalweg vermittelt wird. 
miR-181a wiederum wird durch bisweilen unbekannte Prozesse während der Keratinozyten-
Differenzierungskaskade erhöht exprimiert und reguliert. Daher schlussfolgerten wir, dass die 
durch gestörte Differenzierungsprozesse verminderte miR-181a Expression zu einer 
Enthemmung von KRAS führt, welches wiederum die Tumorentwicklung begünstigt. 
Ein weiteres wichtiges Tumorsuppressorgen, welches ebenfalls während der Keratinozyten 
Differenzierung reguliert wird, ist CYFIP1. Als negativer Regulator des Arp2/3 Komplexes 
unterdrückt CYFIP1 die zielgerichtete Synthese von Aktinfilamenten, welche die Grundlage der 
Zellmigration darstellt. In unseren Experimenten konnten wir nachweisen, dass CYFIP1 in 
Folge von NOTCH1 Aktivierung ansteigt, mit dem Grad der Keratinozytendifferenzierung 
korreliert und ein vergleichsweise geringes Vorkommen im invasiven SCC aufweist. 
Passenderweise verlieren SCC Zellen mit zuvor dysfunktionalem NOTCH1 ihre invasive 
Neigung, sobald NOTCH1 künstlich wiederhergestellt wird. Ein gleichzeitiger CYFIP1 knock-
down hob diesen Effekt wieder auf. Des weiteren konnten wir eine direkte Interaktion 
zwischen CLS, eines zum NOTCH1 Signalweg gehörendem Transkriptionsfaktors, mit der 
Promoterregion von CYFIP1 mittels ChIP-Assay nachweisen. 
 
Die in dieser Doktorarbeit erlangten Erkenntnisse tragen zu einem besseren Verständnis der 
Vorgänge bei, mit Hilfe derer miR-181a und CYFIP1 die wichtigsten krebsbezogenen Aspekte 
wie unkontrollierte Proliferation und erhöhte Invasion negativ regulieren. Des weiteren 
könnte das neue Wissen direkt bei der Entwicklung von zukünftigen, auf miRNAs basierenden 
SCC Therapien eingesetzt werden. Dank der Entschlüsselung der Regulationsmechanismen, 
welchen die SCC Invasion unterliegt, erscheint der Arp2/3 Komplex als logisches 
therapeutisches Ziel zur Bekämpfung von invasivem und vielleicht auch metastasierendem 
SCC. 
  
2. Summary 
 
Cutaneous squamous cell carcinoma (SCC) represents the second most common skin 
malignancy among the Caucasian population. Within the last decades its incidence hast been 
constantly rising, being, due to its given metastatic potential, responsible for up to 25% of skin 
cancer-related deaths worldwide. A major risk factor leading to SCC is chronic low-level 
exposure to solar UV light, causing characteristic DNA damage which in turn may lead to 
critical cancer driving mutations. The human DNA repair machinery is highly capable in fixing 
UV-induced mutations allowing affected keratinocytes to survive. Severe damage of 
keratinocyte genomes or failure of the DNA repair machinery typically leads to precocious 
keratinocyte differentiation, thereby eliminating these pre-cancerous cells. During this 
process cells migrate towards upper epidermal layers accompanied by characteristic 
morphologic changes and gradual metabolic shut down followed by cell death. During this 
cascade and even after cell death, keratinocytes fulfill important tasks such as a barrier 
function against harmful environmental conditions or bacterial intrusion.  
When worst comes to worst and a damaged keratinocyte evades not only DNA repair, but also 
differentiation, the human immune system usually represents the last resort by attacking and 
eliminating affected cells. This circumstance explains why immunosuppressed patients bear a 
substantially increased risk of developing SCC. Typically, SCC are surgically excised, which 
represents a curative treatment. A small fraction of SCC seeds to dermal blood or lymph 
vessels and may eventually form distant metastasis. Metastasizing SCC is a highly aggressive 
form of cancer with poor survival rate, where only a few treatment options with limited impact 
are available. Therefore, it is substantial to gain knowledge of mechanisms and strategies used 
by keratinocytes to become successfully invasive tumors. 
Physiologic and pathologic processes are not only regulated by changes in the expression of 
protein-encoding genes, but also by alterations in the levels of microRNAs (miRNAs). miRNAs 
are approximately 22 nucleotide-long non-coding RNA molecules binding to the 3' 
untranslated regions (UTR) of target mRNAs in a sequence-specific manner thus influencing 
translation and/or stability of the transcripts. miRNA expression analyses suggest important 
oncogenic as well as tumor-suppressive roles of miRNAs, referred to as tumor-driving (so 
called oncomirs) and tumor-suppressor miRNAs, respectively. They effectively play roles in 
almost all aspects of cancer biology such as in proliferation, apoptosis, metastasis and 
angiogenesis. 
Based on our observation that microRNA-181a (miR-181a) shows lower abundance in SCC 
compared to normal skin, the main aim of this PhD thesis was to investigate its role as a tumor-
suppressive miRNA in SCC. Indeed, by knocking down miR-181a in normal skin, cells acquired 
cancerous characteristics, such as increased proliferation and disturbed differentiation. 
Conversely, reestablishing miR-181a in SCC cells tamed their cancerous behavior, as shown by 
decreased proliferation and induction of apoptosis. We confirmed that the proto-oncogene 
KRAS not only acted as a direct target of miR-181a, but also effectively regulated by miR-181a 
in keratinocytes. In our experiments, KRAS’ oncogenic potential in SCC became evident and 
could be directly ascribed to the negative regulation through miR-181a. Furthermore, KRAS 
mediated its pro-proliferative stimulus via the MAPK signaling pathway. 
Looking upstream, miR-181a seemed to be upregulated by processes during keratinocyte 
differentiation. We hence conclude that disturbed differentiation leads to reduced miR-181a 
levels in SCC and subsequently to critically decreased suppression of KRAS which in turn 
promotes carcinogenesis. 
 
Another tumor suppressor gene tightly connected to keratinocyte differentiation is CYFIP1. As 
a negative regulator of the Arp2/3 complex it interferes with actin plasticity-driven cell 
migration and is therefore associated with the metastatic potential of SCC. Our experiments 
demonstrated that CYFIP1 was strongly induced upon Notch1 activation, correlated with the 
grade of keratinocyte differentiation and showed low abundance in invasive SCC. Functionally, 
SCC cells with defective Notch1 signaling lost their invasive potential upon artificial NOTCH1 
reactivation. A simultaneous CYFIP1 knockdown abolished this effect, driving the cells towards 
cancerous invasion once again. Finally, we proved the direct interaction between CLS, the DNA 
binding transcription factor of Notch1 signaling, and CYFIP1 promotor region. 
 
In summary, the results of the current thesis provide a better understanding of how the 
oncogenes miR-181a and CYFIP1, both activated during keratinocytes differentiation, control 
the main hallmarks of SCC, elevated proliferation and invasion. These novel findings may be 
directly applied in the development of topical miRNA treatments against SCC in the future. 
Insight into SCC’s regulatory network of invasion suggests the Apr2/3 protein complex as a 
novel therapeutic target against invasive and possible also against metastasizing SCC. 
  
3. Introduction 
 
4.1 Skin 
The skin is the largest human organ accounting for 1.6 – 2 m2 depending on the body size. The 
main task of the skin is protection of the organism against environmental conditions such as 
pathogens, toxins, physical stress and climate factors [1]. The organ structure can be divided 
into the outer epidermis, the much thicker dermis and the subcutaneous hypodermis 
consisting of subcutaneous fatty tissue [2]. The dermis is mainly composed out of collagen 
giving it a coriaceous structure. Fibroblasts, mast cells, histiocytes and a large proportion of 
extracellular matrix form the substance crisscrossed by blood capillaries. Dermis and 
epidermis are separated by a thin membrane composed out of collagen IV and laminin called 
basal membrane on which the epidermal cells are anchored. Epidermis and dermis are 
separated by the basal membrane (Figure 1). The epidermis accounts for 0.05 mm to 1.5 mm, 
while the thickness of the dermis ranges between 1.5 mm and 4.0 mm, depending on the body 
site [3]. Keratinocytes are the predominant cell type found within the epidermis, accounting 
for around 95% of the cells. According to their differentiation status the epidermis can be 
vertically divided into stratum basale, stratum spinosum, stratum granulosum and the outer 
most stratum corneum [4]. 
Hair follicles are dispersed over large parts of the organ, housing stem cells for keratinocytes 
and other cell types. A variety of glands ensure skin integrity, water tightness and temperature 
control by excreting different substances [5]. 
 
 
 
Figure 1: Structure of the human skin 
The figure is based on illustrations from webMD.com and skinpilot.de. 
 
 
4.1.1 Cells of the skin 
 
4.1.1.1 Keratinocytes 
The keratinocyte stem cell pool can be found in hair follicles. In their relatively short life span 
of approximately 28 days they spread across the basal lamina and travel towards superficial 
epidermal layers while differentiating [6]. While basal keratinocytes are proliferative, cells of 
outer layers gradually shut down their metabolism and disperse their nuclei resulting in cell 
death. As an important side effect, differentiation of damaged keratinocytes effectively 
neutralizes their oncogenic potential. Furthermore, even terminally differentiated 
keratinocytes are still fulfilling important tasks as “functional corpses” [7]. While their 
differentiation status can be determined relatively easy using microscopy, their molecular 
classification relies on the correct interpretation of differentiation markers. Certain keratins 
like keratin 5 and 14 are mainly found in the proliferating cell layer. Keratin 1 and 10 are 
characteristic for the spinous and granular layer. Especially proteins of the cornified envelope 
like involucrin, filaggrin and loricrin are markers for more advanced differentiation found in 
the stratum corneum [8, 9]. Flaws in the differentiation cascade may lead to keratinocyte 
cancers. Cutaneous squamous cell carcinoma (SCC), for example, is, among other criteria, 
characterized by a disturbed differentiation pattern. Histologically conspicuous features are 
abnormal thickening of differentiated cell layers, called hyperkeratosis, often accompanied by 
the presence of nuclei, referred to as parakeratosis [10]. 
 
4.1.1.2 Melanocytes 
Unlike other skin cells melanocytes originate from the neural crest and travel towards their 
destination, the epidermal basal lamina, during embryonic development [11]. Their main task 
is production and distribution of melanin among keratinocytes, protecting their DNA from UV-
induced damage [12]. Benign accumulations of melanocytes form moles or “nevi”, while a 
malignant transformation to melanoma causes most skin cancer relates deaths (American 
Cancer Society, 2016-08-11). 
 
4.1.1.3 Merkel cells 
Merkel cells are associated with nerve endings within the basal epidermal layer and function 
as mechanosensory organs. Malignant transformations of these cells are very rare, but 
associated with high mortality [13]. 
 
4.1.1.4 Fibroblasts 
Fibroblasts are the predominant dermal cells and produce the fibrous structure giving the skin 
its robustness. In addition, they play important roles in wound healing and communicate 
closely with epidermal keratinocytes [14, 15]. Defects in this communication network may 
lead to formation of SCC on sun damaged skin [16]. 
 
4.1.1.5 Immune cells 
To effectively protect the body against pathogens, the skin is not only a physical barrier but 
an active immune organ [17]. A variety of immunocompetent cells with migratory capacity, 
such as leukocytes, mast cells, monocytes and macrophages can be found in the dermis and 
hypodermis. As mentioned before, the dermis is equipped with lymph and blood vessels and 
contains the majority of immune cells, including, T cells, dendritic cells and others. Therefore, 
most of the immune processes are taking place there. The epidermis, lacking direct access to 
blood or lymph vessels, is mainly equipped with antigen-presenting Langerhans cells, dendritic 
epidermal T cells and relies on basic immune functions of keratinocytes and melanocytes [18].  
4.2 Cancer 
 
 
4.2.1 Basics of cancer – hallmarks of cancer 
 
In complex multi-cellular organisms, such as mammals, every aspect of cellular behavior needs 
to be regulated precisely to ensure flawless operation of the collective.  
Tumor cells vividly demonstrate the sensitive balance of cellular regulatory mechanisms. A 
slew of critical events randomly occurs, thus the control over basic functions of the cell is lost. 
Once a cell evades control and immune system clearance, it gains a strong selection advantage 
over normally functioning cells. The consequences are excessive proliferation followed by 
gradual spreading over large parts of the body. Cells of various tissues will be affected, 
disturbing adequate organ function and eventually leading to death [19]. 
In two reports Hanahan and Weinberg summarize the generally accepted cancer 
characteristics as “Hallmarks of Cancer” [20] (Figure 2). The first report discusses how 
proliferative signaling, evading growth suppressors, onset of metastasis, replicative 
immortality, induction of angiogenesis and resistance against cell death enable cancerous cells 
to survive, grow and spread. In their second issue “Hallmarks of Cancer: The next generation”, 
they broaden their discussion, taking so called “enabling” criteria, such as chronic 
inflammation, adaptations and increased flexibility acquired through genomic instability into 
account [21]. Recent pharmaceutical approaches successfully target these hallmarks in some 
malignancies e.g. by kinase inhibition, whereas the cancer in turn quickly reacts by acquiring 
resistance mechanisms [20], making continued research and development indispensable. 
 
 
Figure 2: Hallmarks of Cancer: The next generation [21] 
 
4.2.2 Skin cancer 
 
4.2.2.1 Melanoma and non-melanoma skin cancer 
Skin cancer is roughly divided into melanoma and non-melanoma skin cancer depending on 
the affected cell type. Melanocytes, pigmented cells found in the basal epidermal layer, give 
rise to melanoma [11].  Based on statistical investigations in the US, the National Cancer 
Institute of the NIH estimates 76,380 new cases of melanoma representing 4.5% of all new 
cancer cases in 2016. The disease is responsible for 10,130 deaths in the US per year, 
corresponding to 1.7% of all cancer related deaths [3]. Since the early 1990s melanoma 
incidence has been constantly rising while the number of resulting deaths remains relatively 
constant. This improved outcome is mostly due to early recognition of thin tumors and also to 
advances in treatment options, such as a variety of small molecule inhibitors or highly effective 
immune therapies. Furthermore, the effort invested into increasing the population’s 
awareness led to earlier diagnosis of Melanoma. In its early stage, where no vessel invasion 
and metastasis formation takes place, the 5-year survival rate is 98.4% and drops dramatically 
to 17.9% at later stages when distant metastasis are present [3]. 
All other skin cancers originate from cells other than melanocytes, and are referred to as non-
melanoma skin cancer [22]. The great majority, approximately 80%, of all non-melanoma skin 
cancers are basal cell carcinomas (BCC). Although the incidence has been constantly rising to 
three million Americans diagnosed in 2016 [19], BCC-related deaths are rare, mostly due to its 
low metastasizing potential. Furthermore, the available treatment options, for the majority 
surgical excision and rarely hedgehog pathway inhibitors result in reliable BCC clearance or 
control [23-25]. Previously, BCC was thought to arise from the basal keratinocytes, while later 
studies consider keratinocyte stem cells of the hair follicle bulge as its origin [26, 27]. 
The second-most frequent non-melanoma skin cancer is SCC which typically arises from 
keratinocytes found on the basal epidermal layer or from hair follicle-associated cells [28, 29]. 
Other non-melanoma skin cancers are Merkel cell carcinoma, cutaneous T-cell lymphoma or 
Kaposi’s sarcoma, for example, accounting for less than 10% of skin cancers, depending on the 
geographical region and other factors [30]. 
 
4.2.2.2 AK as in-situ SCC and invasive SCC 
 
 
4.2.2.2.1 Overview 
 
In-situ SCC in the form of actinic keratosis (AK) or Bowen’s disease is typically found on sun 
exposed sites of the body, such as the face, lower arms and the balding head [31]. Depending 
on the vertical spreading within the epidermis, AK can be classified as keratinocyte 
intraepidermal neoplasia (KIN) I – III. KIN I describes AK of the basal third of the epidermis, KIN 
II affects the lower two thirds and KIN III concerns the whole epidermis [32]. AK is histologically 
characterized, among other features, by abnormal keratotic thickening and the presence of 
nuclei in terminally differentiated keratinocytes, referred to as hyperkeratosis and 
parakeratosis respectively. Since chronic UV exposure is seen as the major AK cause, these 
histologic hallmarks are found in a pattern intermitted by hair follicles, which provide light 
protection resulting in unaffected epidermal regions within their proximity. As AK progresses 
to invasive SCC, it acquires more general cancer characteristics, such as pleomorphic cells, 
hyperchromatin, hypereosinophilia or immune cell infiltration. More SCC-specific structures 
are small nests of keratinization within the tumor, such as keratin pearls, consisting of more 
differentiated spots. Furthermore, various cyst-like structures of terminally differentiated 
keratinocytes can be found, making SCC histologically a highly irregular tumor [33, 34] (Figure 
3). Since poorly differentiated SCC is associated with worse patient outcomes, the overall 
differentiation state may offer valuable clues towards cancer prognosis [35]. 
 
 
Figure 3: Histological features of AK and SCC. 
(1) hyper keratosis (2) parakeratosis (3) keratotic pearl (4) immune cell infiltration. 
Modified from [34] and http://www.mrcophth.com. 
 
SCC is typically found in elderly Caucasians with fair skin, where males are significantly more 
likely to be affected than females. SCC incidence has dramatically increased within the last 
decades with more than one million cases diagnosed in the U.S. each year and a death rate of 
approximately 2% [36, 37]. Although the population’s awareness of the risks posed by solar 
UV is steadily increasing, the long latency of the disease is made responsible for the current 
situation where older generations are mainly involved. Geographically, regions with high UV 
exposure, like Australia and New Zeeland, are most affected [38]. Chronic low-level exposure 
to UV, during leisure time and up in the mountains for example, have a major impact on SCC 
formation, possibly explaining the high incidence in countries like Switzerland.  
 
 
 
 
4.2.2.2.2 Molecular pathogenesis of SCC 
In order to fulfill their functions in the human body, keratinocytes need to be permanently 
subject to tight control communicated via complex cell signaling pathways. The most 
important carcinogenic factors and the according molecular consequences which may lead to 
SCC formation will be introduced in this section. 
 
4.2.2.2.3 The impact of UV light 
Typical sites for SCC formation are the face, balding head, lower arms and the dorsum of the 
hands, indicating the crucial role of chronic ultra violet (UV) exposure in tumor development 
and progression. According to their wave length and the correlating energy, UV light is 
separated into UVA (320 nm – 400 nm, low energy), UVB (280 nm – 320 nm, medium energy) 
and UVC (< 280 nm, high energy). Due to atmospheric absorption the natural occurrence of 
UVC is rare and has an accordingly minor role in SCC development [39]. In contrast, solar UVA 
and UVB light penetrate deep into epidermal and dermal skin layers with severe impact on 
the cells [40]. UVB directly induces chemical reactions leading to DNA mutations during DNA 
replication.  Neighboring pyrimidines are most vulnerable as UVB irradiation frequently leads 
to formation of cyclobutane pyrimidine dimers (CPD)or pyrimidine (6-4)pyrimidones (64PPs). 
The pyrimidine cysteine within these photoproducts is unstable and tends to deaminize 
spontaneously, leaving an uracil instead. Since uracil is under natural circumstances found 
exclusively in the RNA, but not in the DNA, it is replaced with the according DNA base 
thymidine during DNA repair resulting in C -> T mutations [41, 42]. To some extent UVA light 
is known to induce these direct photo reactions as well, but the more common UVA reaction 
is the generation of reactive oxygen species (ROS). ROS attack DNA causing double-strand 
breaks and derivatization of guanine to 8-hydroxyguanine (8OH-G), which in turn may result 
in point mutations [43]. 
The importance of permanent and reliable DNA repair is vividly demonstrated by patients 
suffering from xeroderma pigmentosum (XP), a rare autosomal recessive genetic disorder of 
DNA repair. Any UV-induced DNA damage here is translated largely unbridled into cancer 
formation [44, 45]. 
 
 
4.2.2.2.4 The impact of immunosuppression 
Organ transplant recipients (OTR) carry a dramatically elevated risk of forming SCC [46]. More 
specifically, this patient group faces a life time risk of up to 90% to suffer from SCC and a 250-
fold increased risk relative to the general population. Furthermore, they are exposed to an 
increased risk of forming severe forms of SCC, such as field cancerization or metastasizing SCC 
[47]. In turn, SCC represents by far the most common cancer within this patient group [48]. 
The restrained immune system clears cancerous cells within the skin less effectively resulting 
in improved survival of malignant cells in turn leading to full-blown cancer. Kidney and heart 
transplant recipients receive higher doses of immunosuppressants compared to liver 
transplant recipients, where lower doses are sufficient to prevent organ rejection. SCC 
occurrence among those patient groups clearly correlates with the degree of immune 
suppression further underlining the importance of a competent immune system in 
maintaining skin homeostasis [49, 50]. Besides these indirect effects, many studies point out 
various direct mechanisms in which the immune suppressing drugs itself, such as the 
calcineurin inhibitor cyclosporine A (CsA), promotes cancer formation [51]. Research in our 
own laboratory, contributed to the understanding of how the AP1 transcription factor family 
member, activating transcription factor 3 (ATF3) is potentiated through two different signaling 
pathways to induce excessive keratinocyte proliferation. On the one hand UVA induced ATF3 
expression through ROS-mediated nuclear factor erythroid 2-related factor 2 (NRF2) 
activation while nuclear factor of activated T cells (NFAT), a negative regulator of ATF3, was 
suppressed by CsA mediated calcineurin inhibition. Induced ATF3, subsequently, inhibited p53 
expression resulting in keratinocyte carcinogenesis (Figure 4) [52]. 
 
 
Figure 4: CsA in combination with UV light potentiates ATF3 to form SCC in OTR patients 
[52] 
 
Another immunosuppressive drug, azathioprine, has been shown to directly generate a 
chaotic pattern of DNA mutations in combination with UV light. 6-thioguanine, the active 
compound of azathioprine, functions as a DNA/RNA analogue and is incorporated into the 
genome of, mainly immune cells with consequences to their function. As a side effect, 6-
thioguanine generates ROS upon UV absorption which in turn may lead to critical cancer 
causing mutations in keratinocytes [53]. 
Mammalian Target of Rapamycin (mTor) inhibition represents an alternative strategy for OTR 
to achieve adequate immunosuppression, causing fewer side effects and a much lower DNA 
mutation frequency. After the introduction of mycophenolate mofetil, which benefits from 
antiproliferative properties combined with unchanged photosensitivity in patients, 
azathioprine was gradually pushed back from the market [54]. 
 
 
 
 
 
 
4.2.2.2.5 Characteristic mutations in SCC 
 
 
Primary melanoma, for example, is characterized by very frequently occurring mutations in 
BRAF and NRAS. The situation in SCC, on the other hand, is much more heterogeneous with a 
diffuse pattern of mutations, largely unrelated to SCC staging. However, there are a few 
mutations prevalent in SCC, which will be summarized in the following paragraphs [55]. 
 
4.2.2.2.5.1 P53  
P53, or tumor protein p53 (TP53) in humans, plays a central role in preventing UV induced 
carcinogenesis and is nicknamed “the guardian of the genome”. In its steady state p53 is 
subject to a balance of constant production. DNA damage leads to chemical modification of 
p53, reducing its degradation and thereby resulting in p53 accumulation [56]. Stabilized p53 
activates multiple tumor suppressive pathways like p21 activation and initiation of DNA repair 
mechanisms leading to cell cycle arrest [57] degradation [58, 59]. In case of failed DNA damage 
repair the cell is usually forced to undergo apoptosis or differentiation, in the case of 
keratinocytes [60]. Mutated p53 loses its DNA binding capability and fails to activate the 
sequential tumor suppressive gene expression cascade [61]. A large proportion of non-
melanoma skin cancers harbor p53 loss-of-function mutations in association with a clear UV 
signature on their DNA. 60% of AK are associated with p53 mutations, and a study on invasive 
SCC, for example, observed p53 mutations in 58% of the cases [62, 63]. Notably, p53 mutations 
can already be found in normally appearing keratinocytes of UV exposed skin areas. 
 
4.2.2.2.5.2 Notch signaling 
Notch signaling represents a very basic pathway for cell-cell communication, is highly 
conserved and therefore found in almost all multi-cellular organisms [64]. Notch ligands are 
commonly cell surface components and require direct cell-cell contact in order to activate 
Notch signaling. Thereby, groups of neighboring cells gain the ability to organize themselves 
as observed in lateral or contact growth inhibition. On top of that, cell-cell contact signaling 
via Notch can determine cell fate and plays crucial roles during embryonic development. 
Mammals possess four different Notch receptors, referred to as NOTCH1, NOTCH2, NOTCH3, 
and NOTCH4 [65, 66]. 
As a single-pass membrane protein, Notch receptor spans the cell membrane and can be 
divided into an extra- and intracellular domain. Upon ligand binding to the extracellular 
domain, the signal is transferred to the intracellular domain, where proteolytic cleavage takes 
places [64, 67]. This reaction releases a component of the intracellular domain which 
translocates into the nucleus where it associates with the DNA-binding protein CSL and an 
ancillary protein, MamL1 or related family members. The resulting transcription factor 
complex interferes with target gene expression. Among others the best characterized targets 
of NOTCH1, the prevalent family member in the skin, are HES1, p21 and IRF6 [68, 69]. 
While Notch activation in the skin is mainly connected to cellular differentiation and 
suppression of growth, its depletion in the brain leads to precocious neural differentiation 
during development. Therefore, Notch acts as a tumor suppressor as well as an oncogene 
depending on the organ, making the signaling pathway highly context specific [70, 71].  
Human skin relies on functioning Notch signaling to maintain its homeostasis. Keratinocyte 
differentiation is triggered by Notch activation, and loss of function may cause skin cancer 
formation [72]. The molecular mechanisms downstream of Notch activation that elicit 
differentiation remain elusive.  
The communication between dermis and epidermis partly relies on Notch signaling. Hu and 
colleagues showed in an in vivo model, that mice with dermal NOTCH1 depletion rapidly form 
SCC on multiple sites of the body [16]. In vitro SCC cell lines like SCC13 are unable to 
differentiate due to defects in NOTCH1 signaling, which can be seen as the main factor 
responsible for their rapid and uncontrolled proliferation. Artificial NOTCH1 knock in 
reestablishes their capability to differentiate and rescues their cancerous behavior [69].  
 
4.2.2.2.5.3 ΔNp63 (p40) 
P63, a p53 family member, is highly expressed in squamous epithelium and to some extent 
also in normal basal cells, myoepithelial cells, trophoblasts, thymic epithelium and urothelium. 
P63 has two predominant and clinically relevant isoforms, TAp63 and ΔNp63 with opposing 
functions [73]. While TAp63 functions as a tumor suppressor, similar as p53, ΔNp63 acts as its 
agonist and can therefore be seen as an oncogene [74, 75]. Detectable ΔNp63 expression is 
very specific to SCC allowing reliable distinction between normal skin and other neoplasia in 
routine clinical diagnostics [76]. 
 
4.2.2.2.5.4 Wnt signaling 
Wnt signaling has recently been identified as altered in SCC with evidence for functionality in 
SCC formation and progression [55, 77]. 
In the absence of Wnt in canonical Wnt signaling, β-catenin is subjected to a fine balance of 
permanent expression and degradation. Upon activation through Wnt ligands binding to 
seven-pass transmembrane-containing Frizzled (FZD) receptors, β-catenin degradation is 
interrupted resulting in accumulation and translocation into the nucleus where oncogene 
expression is initiated [78]. Different canonical and non-canonical Wnt signaling variants are 
summarized under the term Wnt signaling network [79, 80]. LGK974, a small-molecule Wnt 
signaling inhibitor, is well tolerated, and highly efficacious in human head and neck SCC cells 
[81], suggesting that it may prove beneficial in other SCCs with hyper-activated Wnt/β-catenin 
signaling [77]. 
 
4.2.2.2.5.5 TERT 
The TERT (telomerase reverse transcriptase) gene encodes for the catalytic subunit of 
telomerase. By elongating the chromosomal telomeres, the enzyme prevents their shortening 
during DNA replication allowing the cells to maintain stemness and become potentially 
immortal. This mechanism is used by various cancer cells to evade senescence and apoptosis 
during uncontrolled proliferation, making TERT mutation a common feature found in BCC and 
SCC [82]. 
 
4.2.2.2.5.6 CDKN2A 
The CDKN2A (cyclin-dependent kinase inhibitor 2A) gene encodes for p16, a potent tumor 
suppressor protein. By binding to cyclin-dependent kinases 4 and 6 it prevents their 
interaction with cyclins, leading to G1 cell cycle arrest. Additionally, p16 is known to induce 
Notch-dependent differentiation in keratinocytes. Therefore, cancer cells acquiring CDKN2A 
mutations evade senescence and cell-cycle arrest [83, 84]. 
 
4.2.2.2.5.7 The Ras family 
Mammalian cells express, among others, three closely related Ras proteins: HRAS, KRAS and 
NRAS known as the core Ras family. Mutationally activated at codons 12, 13 or 61, these small 
GTPases promote oncogenesis in a variety of organs, such as the lung, pancreas or intestine 
[85], mostly by overactivating MAPK signaling [86]. The molecular mechanisms and other facts 
concerning small GTPases, specifically Ras family members, will be described in more detail 
below. 
 
4.2.2.2.5.7.1 KRAS 
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a small GTPase. This class of signaling 
molecules characterized by hydrolase activity can bind and hydrolyze guanosine triphosphate 
(GTP) to form guanosine diphosphate (GDP). In its inactive state it is bound by GDT while 
association with GTP activates KRAS. 
So called GTP-exchange factors (GAP) activate KRAS by swapping GDP with a GTP molecule. 
Given that small GTPases possess hydrolase activity, they can switch themselves off by 
processing GTP into GDP. Due to their low enzymatic potential, however, small GTPases are 
supported by GTPase activating proteins (GAP) accelerating the process drastically [87, 88].  
KRAS plays a central role in cell signaling. Upstream it is typically activated by receptor tyrosine 
kinases (RTK) and downstream KRAS activates various signaling pathways regulating various 
functional aspects in normal tissue (Figure 5). A single amino acid mutation however can 
prevent GTP hydrolyzation leading to constitutively active KRAS as seen in many cancers, such 
as colon cancer or non-small cell lung cancer (NSCLC) [89-91]. 
Besides mutations of KRAS itself, several circumstances may lead to critical gain of function. 
Jammed KRAS degradation, elevated transcription or faulty posttranscriptional control 
through miRNAs are to be mentioned as examples [92, 93]. 
 
 
Figure 5: Illustration of small GTPases (or KRAS) and their major mediators. 
 
 
4.2.2.2.5.8 MAPK signaling pathway 
The mitogen activated protein kinase (MAPK) signaling pathway consists of a cascade of 
typically three kinases which are successively phosphorylated. The core MAPK branch consists 
of RAF – MEK – ERK and is usually activated by Rho or Ras family members such as KRAS.  Other 
canonical branches involve p36, JNK and ERK5. In healthy tissue several MAPK branches 
regulate functional aspects from metabolism to apoptosis in concert. Thereby, Extracellular 
regulated MAP kinase 1/2 (ERK) usually takes over stimulatory roles while p38 for example 
has a rather decelerating character (Figure 6) [94, 95]. Due to its central role in cell signaling 
the MAPK pathway is frequently hyperactive in cancer, either due to activating mutations of 
its own kinases, BRAFV600E for example, or by uncontrolled upstream activation, through 
growth factor receptors and GTPases [86, 96]. As discovered in our own research, MAPK 
signaling exhibits a controversial role in SCC. While a mild activation, achieved by suppressing 
negative regulators for example, is connected to carcinogenesis, hyperactivation may result 
in oncogene-induced senescence [97]. 
 
 Figure 6: Branches of MAPK signaling [94]. 
 
4.2.2.2.6 Prevention of SCC 
Since UV light is seen as the major cause for AK and SCC formation, awareness and prevention 
against its dangerous potential are advised. Long sleeve clothing and the use of sun screen 
provide the most effective protection against UV irradiation of the sun [98]. Individuals with 
immune suppression, such as OTR or HIV positive patients, are much more likely to develop 
SCC when exposed to UV light. Keeping track of their daily UV exposure, by the use of UV 
sensors, may help these patient groups to effectively reduce their risk of developing UV 
induced SCC [99]. 
4.2.2.2.7 Treatment options against AK and SCC 
The earlier treatment for SCC is initiated, the fewer the complications that are to be expected 
and the higher the success rates. Therefore, diligent treatment of AK as in-situ SCC is advised 
[100]. In the context of SCC treatment, one needs to distinguish between different stages of 
SCC, where topical treatments in the form of creams are rather applied in early stages of AK. 
Field cancerization typically undergoes field treatment, while single lesions are subject to 
cryotherapy. Invasive SCC are excised surgically to prevent metastasis formation [101]. 
 
4.2.2.2.7.1 Photodynamic therapy 
Photodynamic therapy (PDT) is a frequently applied topical treatment mainly against AK. 
Aminolevulinic acid as a prodrug is applied to the treatment area. After or during conversion 
of this prodrug to the active form of protoporphyrin IX, the photodynamic effect is induced by 
daylight or selective light sources [102]. As a result, ROS are generated, resulting in destruction 
of cell walls and secondary tumor ischemia. [103, 104]. PDT results in sustained lesion 
clearance in 78% to 100% of all cases, making it a very reliable and successful treatment option 
[105, 106]. 
 
4.2.2.2.7.2 5-Fluorouracil 
5-Fluorouracil (5-FU) is a chemotherapeutic agent, aiming to interrupt thymidine synthesis 
and thereby DNA replication. With intermediate treatment duration and in spite of transient 
inflammatory reactions, it is still used nowadays [107]. 
 
4.2.2.2.7.3 Diclofenac 
Diclofenac exhibits anti-inflammatory effects by inhibiting cyclooxygenase-2 (COX‐2) and is 
known to induce apoptosis in cancer [108]. Diclofenac is applied topically in combination with 
hyaluronic acid two times a day for up to three months. Sustained lesion clearance is achieved 
in up to 40% of the cases [109]. 
 
4.2.2.2.7.4 Imiquimod 
Imiquimod stimulates the innate immune system by binding to Toll like receptor 7 (TLR 7), 
leading to an interferon-α response mediated by NFkB signaling [110]. Its efficacy has been 
investigated in several studies with varying results. Cancer clearance was observed, on 
average, in around 50% of the cases depending on the study. The treatment duration accounts 
for 16 weeks and the compound is usually well tolerated provoking relatively mild skin 
reactions [111, 112]. 
 
4.2.2.2.7.5 Ingenol mebutate 
Ingenol mebutate (IM) was recently approved under the name Picato for the treatment of AK. 
It is distinguished from other topical treatments by an extremely fast response rate of only 
hours after application. The cream containing IM has to be applied for only two to three days, 
resulting in cancer clearance in more than 50% of the patients, depending on the clinical study 
[111, 113]. Results from our own group identified IM as a strong protein kinase C (PKC) agonist, 
which in turn overactivates the MAPK signaling pathway [97]. Unlike in many other cancers, 
excessive MAPK activation leads to induction of apoptosis in keratinocytes, referred to as 
“oncogene-induced senescence” sometimes [114]. Furthermore, IM is known to induce 
inflammation and necrosis resulting in temporary disfiguration. IM’s simple use results in high 
patient compliance and can be self-applied conveniently at home.  
 
4.2.2.2.7.6 Radiotherapy 
Radiotherapy is also used to treat AK and SCC field cancerization on larger surfaces. Due to its 
excellent cosmetic outcome it is often applied on facial and balding scalp regions. The typical 
procedure comprises six sessions within a period of three weeks. Although mild X-rays cause 
very few side effects, the risk of secondary malignancies in the long-run should be considered 
[101, 115].  
 
4.2.2.2.7.7 Surgical methods 
As mentioned above, SCC holds a substantial risk of metastasis, increasing with disease 
progression. Therefore, invasive SCC is usually excised with a generous safety margin and 
subsequent histologic checkup to ensure complete tumor clearance [116]. In order to keep 
the safety margin as small as possible on critical body sites like the face, excision and 
histological checkup are executed in parallel in a step by step manner, known as Mohs surgery 
[117]. 
A quicker and therefore cheaper method is cryotherapy, where single lesions are iced by 
directly applying a stream of liquid nitrogen. Although this technique is highly efficient, it is 
limited by the hypopigmentation associated with intense use [118]. 
 
4.2.2.2.7.8 Therapies against metastatic SCC 
Up to date there is no curative treatment available for metastasizing SCC. Depending on the 
individual situation, a combination of radiotherapy and chemotherapy may come into 
operation accompanied by surgical excision of accessible metastasis. Chemotherapeutics, 
such as cisplatin or doxorubicin, induce severe side effects, yield uncertain success and have 
therefore a rather palliative character [119, 120]. Due to good results achieved by immune 
checkpoint blockade and targeted therapies, using small molecule inhibitors, in melanoma, 
some studies are currently investigating their therapeutic potential against metastatic SCC 
[121]. 
 
4.2.2.2.7.9 Future miRNA treatment 
Reagents, derived from transfection agents and applied like a cream, are currently being 
optimized for efficient RNA/DNA delivery into profound layers of the human skin. These 
vehicles could give rise to a microRNA based treatment against SCC in the future [122, 123]. 
This topic is discussed in the microRNA part in more detail. 
 
  
4.2.2.3 Metastatic SCC 
While BCC rarely metastasizes (0.0028 – 0.05% of all cases), SCC holds a substantial risk of 
forming near or distant metastasis (0.1 – 10% of all cases) associated with poor patient 
outcome and only 25 - 50% 5-year survival rate [124]. Common risk criteria for SCC to form 
metastasis are tumor size greater than 2 cm, advanced depth of invasion and critical sites of 
lesions [125, 126]. Presumably, a thick subcutaneous fat layer provides some protection 
against invading SCC cells, explaining the increased metastatic probability reported form SCC 
of the ear, where no significant fat layer is found [101]. Other risk factors are poor 
differentiation, and conspicuous histological subtypes, such as desmoplastic SCC [127].  
 
A generally accepted circumstance promoting metastasis formation in SCC is 
immunosuppression especially via calcineurin inhibition. Hojo and colleagues demonstrated 
the direct effect of cyclosporine on cell morphology and behavior. Prominent pseudopods, 
increased cell motility, and invasive growth, which may be related to transforming growth 
factor β (TGFβ) production, could be ascribed to cyclosporine exposure [128].  
 
 
4.2.2.3.1 Cellular invasion 
In order to leave the primary tumor site and spread into distant regions of the human body, 
cancer cells must undergo a number of molecular and morphologic changes. Epithelial to 
mesenchymal transition (EMT) is a process used by many cancer cell types to leave their 
habitat and invade blood or lymph vessels. Cell adhesions, like desmosomes and 
hemidesmosomes, are cut and matrix degrading proteases are activated enabling the 
epithelial cell to adopt more mesenchyme-like features and move within tissues [129-131]. 
Another EMT feature is loss of basal-apical polarity and cytoskeletal rearrangements resulting 
in active migratory movements as described in more detail in the following section. 
 
4.2.2.3.2 Cellular motility 
A variety of cells in the human body, like immune cells or various stem cells, exhibit migratory 
capabilities [132, 133]. While sperm cells, for example, use their flagellum to propel 
themselves through liquids, most of the other motile cell types adopt amoeboid strategies 
allowing them to glide through the relatively tight structures of organ tissues [134, 135]. This 
movement is achieved by extension of the cell membrane, alternating detachment and 
attachment to the substratum, forward flow of cytosol and retraction of the rear cell 
compartment [136, 137].  Formation of distinct membranous protrusions, so called 
lamellipodia, filopodia and cell membrane ruffles, can be observed on the leading edge while 
the main body mass is located at the trailing edge. The movement is mediated by a 
combination of reorganizations comprising the cell membrane and the cytoskeleton. Rear 
membrane sections are endocytosed at the trailing edge, transported into the direction of 
movement and reinserted into leading edge membrane sites, resulting in a membrane flow 
and gliding-like cellular movement [138, 139], referred to as “blebbing or membrane flow” 
[140, 141]. The driving force is mainly mediated by dynamic and site specific polymerization 
and demolition of actin fibers, resulting in a treadmill like motion and bulging of lamellipodia 
[137, 142]. De‐novo synthesis of actin filaments is catalyzed by the Actin related protein2/3 
complex (Arp2/3) in the leading edge, underlying a complex molecular regulation. Rho GTPase 
family members (e.g. RhoA, Cdc42 and Rac) function as molecular switches, processing 
signaling inputs into directed actin assembly by Arp2/3 complex. This intersection is relayed 
and enhanced by a family of regulatory proteins, including Wiskott–Aldrich syndrome protein 
(WASP), neural (N)-WASP and WASP family verprolin-homologous (WAVE) proteins [143-145]. 
This complex group of regulatory proteins is sometimes referred to as the WAVE complex 
which can be seen as an activator of Arp2/3 propelling cellular migration. Despite its activation 
role the WAVE complex harbors some negatively regulating subunits that may act as tumor 
suppressors (Figure 7). A very important candidate in this context is Cytoplasmic FMR1 
interacting protein 1 (CYFIP1) which is disabled in many epithelial cancers and its loss is 
connected with worse outcomes [146] [147]. Histological data collected by the publicly 
available database “Human protein Atlas” (www.proteinatlas.org, 2016-10-11) shows weak to 
moderate cytoplasmic CYFIP1 abundance in the majority of invasive cancer tissues suggesting 
tumor-suppressive significance far beyond epithelial cancers. CYFIP1 is a RAC-1-interacting 
protein which transmits signals from RAC1 to the Arp2/3 complex by modulating the activity 
of the WASP family members, WAVE1‐3, within the WAVE complex [148].  Furthermore, in 
vitro models show downregulated CYFIP1 during cellular invasion and migration. CYFIP1-
mediated depletion of WAVE function reduced epithelial adhesion and led to disorganization 
of tissue architecture [147]. 
 
Figure 7: Mechanisms of keratinocyte cell migration. 
Modified from http://jonlieffmd.com 
  
3.3 Strategies of gene regulation / differential gene 
expression 
 
Every cell of the human body possesses practically the same genetic information and still 
undergoes individual cell type specific differentiations enabling it to fulfill its highly specified 
duties. The dogmatic succession alone, describing DNA transcribed into mRNA followed by 
protein translation [149], cannot explain the versatile outcomes of cellular development and 
homeostasis. A variety of control mechanisms is necessary enabling different interpretations 
of the same genetic information underlying each cell. Control mechanisms intervening within 
the transcriptional level are subdivided into two groups. While chromatin reorganizing factors 
control general chromatin accessibility by unpacking condensed, inaccessible DNA present as 
heterochromatin into accessible euchromatin, other regulatory proteins termed transcription 
factors directly bind DNA motives, influencing the expression of the according genes [150, 
151]. Post-transcriptional regulators, like RNA binding proteins or miRNAs determine the fate 
of the mRNA in a promoting or inhibitory way [152, 153]. Furthermore, alternative splicing 
partially alters the information encoded on the mRNA resulting in differential protein 
outcomes. Post-translational regulatory factors may influence protein functionality by 
subjecting them to proteasome degradation through specific ubiquitination for example 
(Figure 8) [154].  
 
 
Figure 8: Regulatory mechanisms of gene expression – a schematic overview. 
 
 
3.3.1 MicroRNAs 
 
 
3.3.1.1 Overview 
microRNAs (miRNAs) are a relatively novel class of small non-coding RNA molecules of about 
22 nucleotides in length. By interfering with transcripts they play vital roles in 
posttranscriptional control of most mammalian genes. miRNA deregulation is associated with 
a variety of diseases, ranging from myocardial infarction to autoimmune disease and cancer 
[155]. 
 
3.3.1.2 Discovery and history 
The fundamentals leading to the discovery of the first miRNAs were laid in Caenorhabditis 
elegans (C.elegans) in the early 1990s by Ambros and colleagues [156]. The small nematode 
worm possesses two genes, namely lin-4 and lin-14, vital for larval development. Animals 
harboring null-mutations in the lin-4 gene exhibit severe developmental defects. Interestingly, 
simultaneous deactivated lin-14 reverts the malformed phenotype concluding a negative 
regulatory role of lin-4 against lin-14 [156]. The following search for typical gene features, such 
as start/stop codon, mRNA or even a translation product, remained unsuccessful. 
Furthermore, artificially introduced mutations in lin-4’s putative open reading frame (ORF) 
could not jam the gene’s function, indicating that lin-4 is anything else, but a regular gene. 
During the investigations, researchers encountered conspicuous short non-coding lin-4 
transcripts of unknown function. One of these transcripts has a length of approximately 22 
nucleotides and exhibits characteristic complementary sequence matches within the 3’UTR of 
lin-14’s mRNA. A novel regulatory mechanism involving a small non-coding RNA was 
discovered [156, 157]. 
Until the discovery of the second miRNA, let-7, miRNAs were thought to be a phenomenon 
specific to C.elegans. Subsequently, let-7 family members and other miRNAs were found to be 
abundant in both invertebrates and vertebrates, including humans [158, 159]. Some of the 
miRNAs are highly conserved, suggesting that miRNA-mediated post-transcriptional 
regulation is a general regulatory function across species [158]. Today, thousands of miRNAs 
are known and their diverse functions in several biological aspects are gradually being 
discovered. Novel computer programs access large data bases and facilitate target prediction, 
which is essential for deciphering miRNA functionality [160]. 
 
3.3.1.3 Biogenesis 
Most of the miRNA are encoded in exons/introns of protein-coding or non-coding genes, using 
them as so called “host genes” [161-163]. 
microRNA biogenesis is a complex multistep process starting with a regular transcription by 
RNA polymerase II in the nucleus [164]. The initial transcript shows mRNA features, like a 5’ 
cap and a 3’ poly-A tail, and forms one or multiple distinct secondary structure known as the 
pri-miRNA containing the miRNA stem loops [165]. DGCR8 or "Pasha" in concert with Drosha 
cleaves off the individual hairpins which are referred to as pre-miRNAs and exported into the 
cytoplasm by Exportin 5. Dicer recognizes the pre-miRNAs in the cytoplasm and cleaves off 
the joining loop as well as overhangs on the opposite site, leaving two imperfectly matched 
mature miRNAs of around 22 nucleotides each behind [166, 167]. In addition to that, a non-
canonic biogenesis pathway is known, where the pri-miRNA is processed by the spliceosome 
before nuclear export, circumventing the requirement for Drosha-mediated digestion in the 
nucleus (Figure 9) [168]. 
 
 
Figure 9: Schematic illustration of canonical and non-canonical miRNA biogenesis. 
 
3.3.1.4 Nomenclature 
Traditionally, miRNAs are named according to their discovery in a simple sequential way. A 
letter after the miRNA number differentiates among multiple members of the same miRNA 
family. In the case of a clear predominance of one mature miRNA strand, the short-lived 
passenger strand is labeled with an asterisk. If none of the strands is predominantly degraded 
or RISC incorporated, they are named according to their pre-miRNA position as 3-prime or 5-
prime (3p or 5p). Mature miRNAs with identical sequence but different originating gene loci 
are suffixed with an additional number in the end. The species is indicated by a three letter 
abbreviation at the very beginning (Figure 10) [169]. 
 
Figure 10: Standardized miRNA nomenclature. miRbase.org and [169]. 
 
3.3.1.5 Function 
In general, miRNAs interact with the 3’UTR of their target mRNAs in a sequence-specific 
manner. Function-determining elements of this interaction are the seed region (usually 
nucleotide 2 – 8 seen from the 5’ end) and single matches further downstream towards the 3’ 
end of the miRNA. While sequence matching within the seed regions is rather stringent, 
downstream matches are thought to stabilize the miRNA – mRNA complex [170-172]. 
Interactions noncompliant with those rules like mismatches within the seed region, target 
sites within 5’UTR or coding region of the mRNA exist and are referred to as non-canonical 
binding sites. They typically require additional sequence matching within miRNA regions 
towards the 3’ end to efficiently repress protein translation [173, 174]. Other factors 
important in determining targeting efficacy include the length of the 3’ UTR, the site position 
within the 3’ UTR, closely spaced miRNA binding sites, seed-pairing stability of the miRNA to 
its target, accessibility of the site, and the target-site abundance of competing binding sites in 
the transcriptome. Due to the imperfection of miRNA – mRNA interactions, a miRNA is capable 
of targeting multiple mRNAs, and vice versa, a mRNA can be targeted by multiple miRNAs 
[175-177]. 
The mechanistic modes used by miRNAs to negatively regulate gene expression are versatile, 
highly complex and partially contradictory. In a huge effort undertaken by Morozova and 
colleagues, several established means of miRNA mediated gene regulation (Cap-40S initiation 
inhibition, 60S ribosomal unit joining inhibition, elongation inhibition, ribosome drop-off, co-
translational nascent protein degradation, sequestration in P-bodies, mRNA destabilization, 
mRNA cleavage and transcriptional inhibition through microRNA-mediated chromatin 
reorganization followed by gene silencing (summarized and reviewed in [178])) have been 
evaluated for their plausibility. Furthermore, they took advantage of a sophisticated computer 
algorithm, allowing them to estimate the predominant mode of action of a particular miRNA 
which is dictated by the relationships among the intrinsic characteristics of its target mRNA 
[179]. In some instances, miRNAs are even reported to be involved in histone modification 
and may even bind to promoters, enhancing gene expression [180, 181]. 
These circumstances result in versatile, tissue and context specific miRNA functionality, 
making miRNA research a highly complex subject.  
 
3.3.1.5.1 RNA induced silencing complex 
miRNAs require a complex protein aggregate for target guidance and execution of their 
versatile functions. The RNA induced silencing complex (RISC) is a multi-protein complex, more 
specifically a ribonucleoprotein, fundamental to miRNA function in mammalian cells [178]. 
Based on processes not yet fully understood, usually one mature miRNA strand is incorporated 
into the RISC while the other one, called passenger strand, is degraded [182]. Recent 
estimations suggest thermodynamic properties of a two nucleotide overhang at the miRNA 5’ 
end to be sensed by members of RISC leading to guide strand selection [183]. The incorporated 
miRNA strand serves RISC as a template for target identification. Thereupon, various miRNA 
gene silencing modes, subdivided into mRNA degradation and inhibition of mRNA translation, 
are initiated [172]. 
Argonaute (Ago) family members, especially Ago 2 in mammals, are key players within the 
RISC complex, directly interacting with the incorporated miRNA and are, among other jobs, 
responsible for target mRNA cleavage [184]. This form of negative gene expression regulation 
is typically found in instances where a near perfect miRNA – mRNA match in present. Mainly 
for lose matches RISC is known to accelerate deadenylation and decapping, drastically 
decreasing mRNA stability and thereby protein expression [172, 185]. Debatably, RISC 
incorporated miRNAs can interfere with mRNAs mechanically, terminating or hindering 
protein translation [186]. Interestingly, some RISC independent mechanisms have been 
described, in which miRNAs achieve translational expression by spatially separating the target 
mRNA from the required translational components [187]. A comprehensive review Pratt and 
MacRae summarized our current understanding of how RISC mediates gene silencing [188]. 
      
3.3.1.5.2 Processing bodies 
Distinct foci, microscopically appearing as small granules within the cytoplasm of eurcaryotic 
cells are called Processing Bodies (P-Bodies) (sometimes termed GW Bodies in mammalian 
cells) and are associated with mRNA turnover [189]. Since most of the proteins essential for 
miRNA functionality, like decapping or deadenylation enzymes, are found within these cellular 
organelles it is estimated that most of the miRNA processes are taking place there [190-192]. 
Next to miRNA induced silencing other mRNA decaying mechanisms, such as nonsense-
mediated mRNA decay, adenylate-uridylate-rich element mediated mRNA decay, are 
associated with P-Bodies [193]. Furthermore, mRNAs are not necessarily degraded with the 
P-Body but can be stored and reenter translation at a given time [194]. The exact mechanisms, 
however, forming the basis of P-Body management are currently being investigated. 
 
 
3.3.1.6 miRNAs and cancer 
As indicated above, miRNAs play vital roles in several biological aspects. Little wonder that 
flaws in this substantial regulatory machinery lead to various diseases and cancer [155, 195]. 
According to their oncogenic or tumor suppressive role, miRNAs are referred to as oncomirs 
or tumor suppressor miRNAs respectively [196]. Their deregulation can lead to imbalanced 
cellular homeostasis resulting in cancerous behavior with increased proliferation or formation 
of metastasis for example. Indeed, a deregulated miRNA pattern has been observed many 
different cancers with impacts on several cancer hallmarks. Although miRNAs are considered 
as gene expression fine tuners, the deregulation of a single miRNA may lead to cancer in some 
instances [197, 198].  Along these lines, modulation of miRNA levels or in other words 
reestablishing miRNA regulation, has achieved cancer remission in a variety of in vitro and in 
vivo experiments. Furthermore, an increasing number of studies have identified miRNA 
candidates as useful biomarkers, allowing diagnosis and prognosis of various human diseases 
[199]. 
 
3.3.1.7 miR-181a 
miR-181a is transcribed from two genes (MIR181A1HG and MIR181A2HG) located on 
Chromosome 2 and 9 [200]. Next to being involved into general cellular processes, this 
particular miRNA candidate is known to be a key player in various cancers. Its role comprises 
involvement in many cancer hallmarks as an oncomir as well as a tumor suppressive miRNA. 
This discrepancy highlights the distinct tissue specificity of miRNAs in physiological processes 
[201]. 
 
 
3.3.1.8 miRNA target identification 
As mentioned above, miRNA – mRNA interactions are highly context specific and need to be 
evaluated in each cell type of interest. First clues in the painstaking search can be drawn from 
bioinformatics predictions. Complex algorithms based on binding energies of miRNA – mRNA 
sequence matching depict several possible interactions, usually spitting out thousands of 
possible targets [202]. The search can be refined using databases like miRTarBase 
(mirtarbase.mbc.nctu.edu.tw), which hold a comprehensive collection of validated molecule 
interactions, sorted according to the validation method [203, 204]. 
Most experimental methods are based on artificial miRNA modulation and subsequent 
quantification of either multiple mRNA expression changes, via a gene arrays or mRNA 
sequencing, or single expression changes, using pPCR or Western blotting [205]. Highly 
sophisticated, and accordingly expensive techniques are Ago pulldown assays where Ago is 
linked to its incorporated miRNA and target and isolated, followed by identification via 
sequencing [206, 207]. 
Finally, the direct interaction between the miRNA and the 3’UTR of its target mRNA has to be 
proven. The gold standard comprises a dual luciferase plasmid, transfected into the cell. 
miRNA interaction with the according 3’UTR, which is part of the construct, will prevent 
translation of the downstream luciferase gene. The degree of translational repression can be 
quantified photometrically [208, 209]. In our study, we used a KRAS overexpressing plasmid 
as a backbone and cloned the 3’UTR of interest upstream of the start codon. Thereby KRAS 
protein expression and the corresponding function can be read out simultaneously proving a 
direct link between the miRNA, the target 3’UTR and the functional consequence. 
 
 
3.3.1.9 miRNA therapy options 
By regulating the majority of the human transcriptome, miRNAs play important roles in 
development, homeostasis and disease [155]. Treatments against inherited diseases, so called 
gene therapies, are extremely challenging. Due to the precise spatiotemporal regulation of 
miRNAs during development, these challenges reach another dimension of complexity, 
supposedly provoking more damage than benefits [210]. miRNA therapies against diseases of 
the adult body however, are much more promising as backed up by examples in hepatitis C 
Virus infection, insulin resistance and cardio-metabolic disease [122, 211-213]. 
Similarly, as in research, most of the therapeutic approaches make use of small DNA/RNA 
molecules or their derivatives interfering with endogenous miRNAs by partial or complete 
sequence complementarity. Thereby, the pathologic miRNA is either subjected to degradation 
or “sponged/trapped” leading to its inactivation in either case [214-216]. 
The reverse approach is the therapeutic application of miRNA mimics, reestablishing 
pathologically low miRNA levels or targeting critical onco genes for example [217]. This 
strategy came to use successfully against cancers using let-7 as a template. miR-34 mimics are 
currently in clinical Phase I trials for treatment of metastasized cancer involving the liver [122]. 
Therapeutic small nucleotide molecules are well elaborated constructs containing chemical 
modifications and sometimes DNA/RNA adducts further improving their stability [218]. Still, 
miRNA inhibitors are easier to design than most small molecule inhibitors, because their 
specificity can be predicted and modified following the rules of Watson-Crick base pairing. 
Furthermore, miRNAs are, in contrast to small molecule inhibitors or protein based drug 
molecules, physiologic antisense nucleotides causing less side effects, like toxicity or excessive 
inflammation [122]. 
The main challenge however, remains efficient and reliable delivery of the miRNA cargo to its 
destination. Huge leaps forward have been recently made by the development of 
nanoparticles and liposomes in targeting solid tumors in mouse experiments via simple 
injection into blood vessels. Enhanced permeability and retention effects, arising from 
pathophysiological abnormalities encountered in solid cancers, facilitate passive delivery of 
these nanocarriers [219]. More specific miRNA delivery is achieved by linking miRNAs to 
different types of moieties, such as cholesterol [218], α-tocopherol [220], CpG-containing 
oligonucleotides [221], or antibody fragments [222]. The vast majority of these strategies 
however, aims at organs with central positions within the blood circulation, like liver, lung or 
kidneys and therefore easy accessibility for systematic treatments. Organs like the skin, in 
contrast, cannot be targeted by those means, since most of the miRNA cargo would be 
trapped in the liver [223]. Extensive efforts are currently undertaken to facilitate miRNA 
delivery into distinct skin regions by refining cream-like formulations for topical skin treatment 
[224-226]. 
  
4. Aim of the Thesis 
 
 
Our group holds a strong research interest in molecular processes underlying formation and 
progression of SCC particularly in regard to laying fundamentals for novel therapeutic options. 
Continuous research efforts resulted in huge leaps in the field of efficient miRNA delivery and 
paved the way for the first miRNA therapies against cancer that are now starting to emerge. 
Inspired by the success of these therapies in early clinical trials and the accessibility of the skin 
for topical treatments we were prompted to find out more about the role of miRNAs, miR-
181a particularly, in SCC. Due to the complex nature of miRNA functionality, these small 
molecular regulators have highly variable functions depending on the cellular environments. 
For many miRNA candidates, completely opposing outcomes have been observed depending 
on the organ in which they are acting. Most of the miR-181a studies in cancer, attest miR-181a 
a cancer promoting role, by accelerating general cancer aspects, such as proliferation. The 
very same miRNA has been shown to inhibit formation of metastasis in other cancers. To date, 
little is known about miRNAs in SCC in general and no report so far investigated the specific 
role of miR-181a in SCC. 
Combating SCC’s tendency of invading into dermal layers and forming distant metastasis 
makes a detailed knowledge of the responsible molecular mechanistic essential. Based on 
studies in other epithelial cancers, we were aiming to unravel CYFIP1’s role as a negative 
regulator of keratinocyte invasion. Furthermore, CYFIP1 is under direct NOTCH1 control 
suggesting a molecular coherence in SCCs that induces cellular differentiation and arrests 
cellular invasion. This study could be of high clinical significance, as it suggests a rationale for 
the relationship between SCC differentiation status and its invasive potential. 
  
5. Materials and Methods 
 
 
5.1 Materials 
 
5.1.1 Cell culture 
 
SCC12 cell line: 
originally isolated from SCC of facial skin of a 60-year old male kidney-transplant 
recipient [227]. 
SCC13 cell line: 
originally isolated from SCC of facial skin of a 56-year old female [227]. 
HaCaT cell line: 
spontaneously immortalized keratinocyte cell line, originally isolated from the 
back skin of a 62-year old male [228]. 
HEK293T cell line: 
Originally are isolated from human embryonic kidneys (HEK). The 293T cells are transformed 
with large T antigen [229]. 
 
Primary keratinocytes: 
Isolated from healthy skin obtained from mammary and abdominal surgery at the 
University Hospital Zurich. 
Primary SCC cells: 
Isolated from SCC specimen, excised at the Department of Dermatology at the 
University Hospital Zurich. 
 
5.1.2 Animals 
Female nude mice (Hsd:AthymicNude-Foxn1<nu>)  Harlan Laboratories Inc. 
 
5.1.3 Reagents 
Agarose       Sigma (A9539) 
Ampicilin       Santa Cruz Biotechnology (210812) 
Antibiotic-Antimycotic (100x)    Gibco® (15240-096) 
Blasticin       InvivoGen (ant-bl-1) 
Bovine Pituitary Extract (BPE)    Gibco® (37000-015) 
CnT07 and basal medium     CELLnTEC (CnT-07) 
Doxycycline       Sigma (D9891) 
Doxycycline, in vivo application    Bioserv (S3888) 
Dulbecco’s Modified Eagle Medium (DMEM)  Gibco® (41966052) 
Epidermal Growth Factor 1-53 (EGF 1-53)   Gibco® (37000-015) 
Fetal Bovine Serum Gold PAA    VWR: 95025-540 
G418 Gentamycine      Roche (04727878001) 
Kanamycine       Sigma (70560-51-9) 
Keratinocyte serum-free medium (K-SFM)   Gibco® (10744-019) 
LB Agar       Scharlau (01-385-500) 
LB Agar (instant mixture)     InvivoGen (fas-bl-s) 
LB Broth       Scharlau (02-384-500) 
NuPAGE LDS Sample Buffer     novex (NP0007) 
NuPAGE Sample Reducing Agents    novex (NP0009) 
PBS Dulbecco without calcium and magnesium  Gibco® (10010-015) 
PMSF        Sigma (P7626) 
Puromycin       Santa Cruz Biotechnology (108071) 
RIpa Buffer       Cell Signaling Technology (#9806) 
TB liquid (instant mixture)     InvivoGen (fas-bl-1) 
Trypsin/EDTA Solution     Merck Millipore (SM-2003) 
Vaseline       BAYER (85403-1EA) 
 
Transfection reagents 
Gene Carrier-1™      Epoche (31-00110) 
INTERFERin       Polyplus (409-50) 
 
 5.1.4 DNA, RNA and derivatives 
 
5.1.4.1 miRNA mimics and inhibitors 
mirVana mimic control #1     Ambion (4464058) 
mirVana miR-181a mimics     Ambion (4464066) 
mirVana inhibitor control #1     Ambion (4464076) 
mirVana miR-181a inhibitors     Ambion (4464084) 
 
 
5.1.4.2 Synthetic constructs 
CYFIP1 putative promotor region    Blue Heron (custom made) 
gBlocks miR-181a-1      IDT (custom made) 
gBlocks miR-181a-2      IDT (custom made) 
gBlocks Notch1 intracellular domain    IDT (custom made) 
 
 
5.1.4.3 siRNA sequences     Qiagen 
control sequence: 5’ – AATTCTCCGAACGTGTCACGT – 3’ 
siKRAS_7: 5’ – CTCCTAATTATTGTAATGTAA – 3’ 
siKRAS_8: 5’ –  AAGGAGAATTTAATAAAGATA – 3’ 
CYFIP1_1: upon request 
CYFIP1_2: upon request 
 
 
5.1.4.4 Primer sequences     Microsynth AG 
36B4 (housekeeping gene) 
Forward: 5’ - GCAATGTTGCCAGTGTCT - 3’ 
Reverse: 5’ - GCCTTGACCTTTTCAGCA - 3’ 
 
CYFIP1 
Forward: 5’ - CTGCACGCGGCTCCTTTCCA - 3’ 
Reverse: 5’- GACAAGATGCAGCGGGGCGT -3’   
 
CYFIP1 promotor region (-2.9k bp) 
Forward: 5’ – TAGAGTGTGCTACTATCTGTC - 3’ 
Reverse: 5’ – ATGAAGGTTTGGTTACCCCC - 3’ 
 
CYFIP1 promotor region (-0.9k bp) 
Forward: 5’ - ATCCAAAGCCCCTGTTTTGC - 3’ 
Reverse: 5’ – GTCTCATCAGATTTCAAAGGG - 3’ 
 
Filaggrin 
Forward: 5’ - TGAAGCCTATGACACCAC - 3’ 
Reverse: 5’ - TCCCCTACGCTTTCTTGT - 3’ 
 
HES1: 
Forward: 5’- GGTGCTGATAACAGCGGAAT - 3‘ 
Reverse: 5’- TGAGCAAGTGCTGAGGGTTT - 3’ 
 
HES1 promotor region 
Forward: 5’ – CCTCCCATTGGCTGAAAGTT - 3’ 
Reverse: 5’ – CCTGGCGGCCTCTATATATA - 3’ 
 
Involucrin 
Forward: 5’ - TCCTCCAGTCAATACCCA - 3’ 
Reverse: 5’ - CAGCAGTCATGTGCTTTT - 3’ 
 
Keratin 10 
Forward: 5’ - GGTGGGAGTTATGGAGGCAG - 3’ 
Reverse: 5’ - CGAACTTTGTCCAAGTAGGAAGC - 3’ 
 
KRAS 
Forward: 5’ - AAGACAGAGAGTGGAGGATGC - 3’ 
Reverse: 5’ - GTGCTGAACTTAAACTTACCAGAT - 3’ 
 
Loricrin 
Forward: 5’ - GCGAAGGAGTTGGAG - 3’ 
Reverse: 5’ - CTGGGTTGGGAGGTACT - 3’ 
 
pIND20 Notch1 
Forward: 5’ - CCGCTACTCACGCTCTGA - 3’ 
Reverse: 5’ - CTGGAAGACACCTTGTGC - 3’ 
 
 
5.1.4.5 Mutagenesis primer sequences    Microsynth AG 
 
Binding site 1: 
forward 
5’ - CTTCTTATTTTTCTTACCAATTGTTCCGGTTGGTGTGAAACAAATTAATGAAGC - 3’ 
reverse 
5’ - GCTTCATTAATTTGTTTCACACCAACCGGAACAATTGGTAAGAAAAATAAGAAG - 3’ 
 
Binding site 2: 
forward 
5’ - GTCCTATAGTTTGTCATCCCTGATTCCGGTAAAGTTACACTGTTCACAAAGGTTTTGTC - 3’ 
reverse 
5’ - GACAAAACCTTTGTGAACAGTGTAACTTTACCGGAATCAGGGATGACAAACTATAGGAC - 3’ 
 
Binding site 3: 
forward 
5’ - CGTATATTGTATCATTTGAGTTCCGGTTCCCAAGTAGGCATTCTAGGC - 3’ 
reverse 
5’ - GCCTAGAATGCCTACTTGGGAACCGGAACTCAAATGATACAATATACG - 3’ 
 
 
5.1.4.6 Plasmids and vectors 
nNERT-neo       U Just, Kiel 
pcDNA3       GP Dotto, Lausanne 
pcDNA3/hNIC       GP Dotto, Lausanne 
pcDNA3-Notch1      GP Dotto, Lausanne 
pGL3-basic       Promega 
pGL4.75-KRAS LCS6m      Addgene Plasmid #44571 
phRL-TK       GP Dotto, Lausanne 
phRL-TK       Promega 
pincoGFP       GP Dotto, Lausanne 
pMD2.G       Addgene Plasmid # 12259 
psPAX2       Addgene Plasmid # 12260 
pTRIPZ        GE Healthcare 
pUNO1 KRAS       Sigma 
RBPjk-luc plasmid      Promega 
rNeo        U Just, Kiel 
 
 
5.1.4.7 Viral particles 
MISSION® Lenti microRNA Inhibitors control #1  Sigma (HLTUD001C) 
MISSION® Lenti microRNA control #1   Sigma (NCLMIR001) 
MISSION® Lenti miR-181a Inhibitors    Sigma (custom made) 
MISSION® Lenti miR-181a     Sigma (custom made) 
 
 
5.1.5 Antibodies 
 
5.1.5.1 Primary antibodies 
Antibody Dilution Supplier 
Anti-ERK 1:1000 Cell Signaling (#9102) 
Anti-p-ERK 1:1000 Cell Signaling (#9101) 
Anti-KRAS 1:200 Santa Cruz Bio. (sc-30) 
Anti-filaggrin 1:200 Santa Cruz Bio. (sc-66192) 
Anti-involucrin 1:200 Santa Cruz Bio. (sc-21748) 
Anti-loricrin 1:200 Santa Cruz Bio. (sc-51130) 
Anti-CYFIP1 1:1000 Merk-Millipore (07-531) 
Anti-actin 
Anti-Notch1 
Anti-p21 
Anti-Hes1 
1:1000 
1:200 
1:200 
1:1000 
Santa Cruz Bio. (sc-47778)  
Santa Cruz Bio. (sc-6014) 
Santa Cruz Bio. (sc-6246) 
Merk-Millipore (AB5702) 
 
5.1.5.2 Secondary antibodies 
Antibody Dilution Supplier 
Anti-rabbit HRP  1:5.000 Cell Signaling (#7074) 
Anti-mouse HRP  1:10.000 Abcam (ab6728) 
Anti-goat HRP 1:8.000 Santa Cruz Bio. (sc-2768) 
Anti-mouse IRDye® 680LT 1:10.000 LI-COR (926-68022) 
Anti-mouse IRDye® 800CW 1:10.000 LI-COR (925-32212) 
Anti-rabbit IRDye® 680LT 1:10.000 LI-COR (926-68023) 
Anti-rabbit IRDye® 800CW 1:10.000 LI-COR (925-32213) 
Anti-goat IRDye® 680LT 1:10.000 LI-COR (926-68024) 
Anti-goat IRDye® 800CW 1:10.000 LI-COR (925-32214) 
Anti-rabbit FITC conjugated 1:25 Dako (F005401-2) 
   
 
5.1.6 Cloning enzymes 
Alkaline phosphatase      NEB (M0290S) 
BamHI        NEB (R0136S) 
BglII        NEB (R0144S) 
EcoRI        NEB (R0101S) 
KpnI        NEB (R0142S) 
Nhel-HF       NEB (R3131S) 
Phusion-HF polymerase     NEB (M0530S) 
T4 DNA ligase       NEB (M0202S) 
Xhol        NEB (R0146S) 
 
 
5.1.7 Kits 
BioCoat Matrigel Invasion Chambers   BD (354480) 
BrdU assy kit       Millipore (2752) 
Dc Protein Assay      BioRad (500-0116) 
Diff Quick       Medion Diagnostics (130832) 
Dual Luciferase assay reporter kit    Promega (E1910) 
FITC Annexin V Apoptosis Detection Kit I   BD (556547) 
Gel DNA Recovery Kit      Zymoclean (D4001) 
Genopure Plasmid Maxi Kit     Roche (03143422001) 
Gibson Assembly® Cloning Kit    NEB (E5510S) 
GoScript™ Reverse Transcription System   Promega (A5000) 
High Pure Plasmid Isolation Kit    Roche (11754277001) 
REAL Detection System (APAAP kit)    Dako (K5005) 
RNeasy® MiniElute cleanup Kit    Qiagen (74204) 
TaqMan microRNA assay (miR-181a)   Life Technologies (4427975-480) 
TaqMan microRNA assay (Z30)    Life Technologies (4427975-1092) 
 
 
5.1.8 Chemicals 
Bovine serum albumin (BSA)     Sigma (A9418) 
Chloroform       Sigma (472476) 
Citric acid       Sigma (251275) 
Dimethyl sulfoxide (DMSO)     Sigma (D4540) 
Dispase II       Roche (04942078001) 
ECL solution       Amersham (RPN2106) 
Ethanol       Sigma (02860) 
FastStart Universal SYBR Green Master (ROX)  Roche (04913914001) 
Formaldehyd (4%, buffered)     Kantonsapotheke Zurich 
Formic acid       Sigma (F0507) 
Glycerol       Fluka (49783) 
Glycine       Sigma (G7126) 
Hexadimethrine bromide     Sigma (H9268) 
Hydrochloric acid (HCl)     Fluka (84415) 
Isopropanol       Fluka (34965) 
Methanol       Sigma (32213) 
Protein ladder      Geneaid (PL0245) 
Saponin       Sigma (8047-15-2) 
Sodium chloride      Sigma (S9625) 
Sodium dodecyl sulfat (SDS)     Sigma (71725) 
TritonX100       Thermo Scientific (85112) 
Trizma® base       Sigma (T1503) 
TRIzol® Reagent      Ambion® (15596018) 
Tween 20       Sigma (93773) 
 
5.1.9 Buffers 
10x SDS-PAGE running buffer 
144 g Glycine 
30 g Trizma® base 
50 ml 20%SDS 
Add H2O to 1 l 
use: 100 ml 10x Running buffer + 900 ml H2O 
 
10x TBS 
60.6 g Trizma® base 
87.6 g Sodium chloride 
Adjust pH to 7.6 with HCl 
Add H2O to 1 l 
 
10x Transfer buffer 
144 g Glycine 
30 g Trizma® base 
Add H2O to 1 l 
use: 100 ml 10x Transfer buffer + 800 ml H2O + 100 ml Methanol 
 
RIPA buffer Cell Signaling (#9806) 
+ 1mM PMSF before use 
 
Stripping buffer 
15 g glycine 
1 g SDS 
10 ml Tween 20 
Adjust pH to 2.2 with HCl 
Add H2O to 1 l 
 
TBS/T (washing buffer for WB) 
100 ml 10x TBS 
900 ml H2O 
0.1% Tween 20 (1 ml) 
 
 
5.1.10 Consumables 
Cell culture dishes      Falcon 
Cell culture flasks      Falcon 
Cell culture well plates     Falcon 
Cloning cylinders      Sigma (C3983-50A) 
Combitips       Eppendorf  
Cover slips (18x18 mm)     Menzel GmbH (BB018018A1) 
Cryo tubes Nalgene      VWR International AG 
Eppendorf tube (1.5 ml, 2 ml)    Eppendorf 
Falcon tubes       Corning Life Science 
Glass slides Superfrost Plus     Thermo Scientific (J1810AMNZ) 
Hyperfilm ECL       Amersham Bioscience (28-9068) 
MicroAmp® Optical 96-Well Reaction Plate   Applied Biosystems 
Nitrocellulose membrane     Amersham Bioscience (10600002) 
PVDF membrane      BioRad (162-0177) 
RNase inhibitor (RNase ZAP)     MBP (7002) 
Scalpels       Swann-Morton (0208) 
Whatman paper      Whatman (514-8013/3030917) 
 
5.1.11 Devices 
FACSCanto       BD Biosciences 
Film developer      Thermo Fisher Scientific 
Microscope CLSM Leica SP5     Leica 
Mini Protean® 3 Cell (electrophoresis system)  BioRad 
Mini Trans-Blot® Cell (transfer system)   BioRad 
Plate reader       Tecan 
Power supply       BioRad 
ScanScope       Aperio 
ViiA7 qPCR machine      Applied Biosystems 
 
5.1.12 Software 
Adobe Acrobat XI Pro      Adobe 
Adobe Illustrator CS6      Adobe 
Endnote X6 Thomson      Reuters 
FlowJo        Ashland 
Gene Ape       biologylabs 
GraphPad Prism 5      GraphPad Software 
Image J 1.47t       National Institute of Health 
Image Studio™ Lite      LICOR 
Microsoft office excel 2010     Microsoft 
ScanScope       Aperio 
 
5.2 Methods 
Experiments were conducted in a bio safety level 2 (BSL2) laboratory according to BAFU 
standards. All procedures were carried out at room temperature unless otherwise stated. 
 
5.2.1 Cell culture 
General maintenance 
HaCaT, SCC13 and HEK293T were cultured in DMEM high glucose supplemented with 10% FCS. 
Gibco’s SMF Keratinocyte medium, supplemented with EGF and Bovine Pituitary Extract (BPE), 
was used for SCC12. Primary patient-derived cells were grown in CnT-07 medium and the 
enclosed supplements. Cells were split after reaching a confluence of 80% to 90% using 
trypsin. 
Several cells were cultivated in a humidified 5% CO2 atmosphere at 37°C. 
Temporally unused cell lines, were stored at -80°C in freezing medium (FBS supplemented 
with 10% DMSO). 
 
Institutional board approval for the use of human tissue was granted; all donors signed written 
informed consent forms in accordance with the Code of Ethics of the World Medical 
Association (Declaration of Helsinki) for experiments involving humans (ethical approval 
number EK647). All samples were obtained from the University Hospital Zurich (Zurich, 
Switzerland). 
 
5.2.2 Generation of primary patient derived cell cultures 
Left over skin from mammary or abdominal reduction surgeries was collected at the University 
Hospital Zürich after patients signed consent forms mentioned above. Using a scalpel, the fat 
tissue was removed from the dermis and discarded. Dermal parts were washed in PBS several 
times and cut into 0.5 – 1 cm2 squared pieces. SCC material was biopsied from excised SCC 
parts not needed for histological diagnosis. By incubating preparations in CnT-07 medium 
containing antibiotics and 10 mg/ml Dispase II at 4°C overnight, the basal lamina was digested, 
allowing separation of dermis and epidermis. The obtained epidermal squares were incubated 
us side down in trypsin for 10 minutes at room temperature followed by rigorous stirring, 
using tweezers, in order to bring keratinocytes into suspension. This step was repeated three 
times in CnT-07 medium. Cell suspensions were pelleted in a standard centrifuge, 
resuspended in fresh full medium, containing antibiotics, and cultured in cell culture flasks.  
 
5.2.3 Viability and proliferation assays 
 
5.2.3.1 WST-1 assay 
2000 – 3000 treated cells/well were seeded into 96 well plates in the according growth 
medium. After 96 hours incubation time the medium was swapped with fresh one containing 
1:10 WST-1 and 10% FCS and put back to 37°C. After a clear color change could be observed 
(approx. 60 minutes, depending on cell line) plates were subjected to photometric 
measurement at 450nm and 620nm reference measurement. Since values around 1 are 
desirable, the plate can be re-incubated on 37°C and re-measured at later time points to 
amplify low value readings. 
 
5.2.3.2 BrdU proliferation assay 
Effects of various treatments on cellular proliferation was assessed by bromodeoxyuridine 
(BrdU) incorporation. After initiation of the indicated treatment, cells were brought into 
suspension and seeded into the wells of a 96 well plate at a density of 2000 – 3000 cells/well 
in the according medium. After attachment, fresh medium containing BrdU reagent was 
added and incorporated for 96 hours followed by fixation. Immunologic BrdU detection and 
optical measurement was carried out as described in the manufacturer’s protocol. 
 
5.2.3.3 Manual cell counting 
20000 – 30000 treated cells/ml were seeded into 3cm petri dishes in the according growth 
medium. After 96 hours incubation time pictures of 3 non-overlapping cell layer sections were 
taken and manually counted using imageJ. 
 
 
5.2.4 Possibilities and limitations of miRNA research 
Generally spoken, the working area and tools need to be RNAse free and proper sample 
cooling needs to be given [230]. 
miRNAs can be artificially upregulated in vitro and in vivo by different means. By transiently 
transfecting small chemically modified RNA/DNA molecules, increased miRNA presence can 
be simulated.  Since the utmost part of the cargo gets stuck in membrane compartments or 
stays floating in the growth medium, the actual amount of active (or RISC incorporated) 
miRNA is hard to estimate [231]. Alternatively, constructs coding for miRNA precursors can be 
integrated in the cellular genome which are channeled into the endogenous miRNA processing 
machinery. This system allows for better fine tuning and can be easily used in vivo due to its 
high robustness [232]. The generation however, is much more work intensive and therefore 
connected to relatively high costs. miRNA knock down, can be achieved analogously, via 
transfection or stable integration of complementary DNA/RNA molecules which trap 
endogenous miRNAs and may additionally induce their rapid degradation [233]. 
Cellular miRNA levels are directly measured by TaqMan qPCR, however, during result 
interpretation special care needs to be taken. While pPCR determination of miRNA levels 
modulated by genomically integrated constructs is common practice, the method is 
considered unsuitable for modulations achieved by transfection of miRNA mimics. Results will 
mirror the total amount of miRNA mimics introduced into the experiment and not only the 
tiny fraction of interest, which are the Ago incorporated molecules [234]. A similar principal is 
true for transiently transfected miRNA inhibitors. During RNA extraction inhibitors and their 
targets are extracted simultaneously meaning that they can still interfere during the qPCR 
experiment. Hence the obtained results do not necessarily mirror the cellular miRNA levels. 
The qPCR based readout of a known miRNA target reflects the cellular situation much closer 
in these instances. Importantly, the tissue specificity of miRNA – mRNA interactions has to be 
taken into account when choosing a target gene for read outs [235]. 
 
5.2.4.1 RNA isolation 
RNA was isolated form pelleted cells or tissue samples using TRIzol (Invitrogen) following the 
manufacturer’s protocol. RNA quality was determined by photometry at 260/280 nm and 
260/230 nm, whereas values above 1.8 were considered suitable. In case of poor quality RNA 
yield, an additional purification using Qiagen’s RNA clean up kit could be performed.  
 5.2.4.2 Reverse transcription and SYBR green qPCR 
Gene expression analyses of coding genes (i.e. long transcripts) was performed using the 
GoScript Reverse Transcription Kit (Promega) and SYBR Green (Roche). 1 µg of total RNA, 
transcribed into cDNA according to the manufacturer’s manual using oligo dT primers and 
diluted 1:3 with H2O. Every well of the sub sequent qPCR reaction loaded with the following 
reagents: 
10 µl FastStart Universal SYBR Green Master (Roche) 
8 µl H2O 
0.5 µl primer solution (10 µM) in each direction 
1 µl cDNA 
 
Each reaction was carried out in quadruplicates alongside a cDNA free negative control and 
36B4 as housekeeping gene. After pipetting, the plate was sealed using a plastic cover and 
centrifuged to remove air bubbles. The PCR reaction was carried out in a Viia7 real time PCR 
machine (AB Applied Biosystems) with the following setup: hold stage (95°C, 10 min), PCR 
stage (95°C, 10 sec; 60°C, 30 sec) repeat for 40 cycles, melt curve stage (95°C, 15 sec; 60°C, 1 
min; 95°C, 15 sec). Relative gene expression was calculated by normalization to the house 
keeping gene and determining fold change of relative gene expression. 
 
5.2.5 Reverse transcription and TaqMan qPCR 
Short transcripts (i.e. miRNAs) on the other hand were analyzed using LifeTechnologies’ 
TaqMan microRNA Assays. The kits implement a twostep procedure where miRNAs of interest 
are transcribed into cDNA using loped primers followed by common TaqMan qPCR. Small 
nuclear RNA (snRNA) Z30 was used as “Housekeeping gene” for normalization. All assays were 
performed according to the manufacturer’s protocols. 
 
5.2.6 Protein quantification 
According to the manufacturer’s protocol, reagents were incubated with the protein lysate for 
30 minutes in the dark. After photometric read out at 690 nm wave length the protein content 
was calculated by comparing it to a standard curve. 
 
5.2.7 Protein isolation 
Cells were washed with ice cold PBS and lysed in RIPA buffer (Cell Signaling Technology) for 15 
minutes followed by centrifugation at 16000xg at 4°C for 20 minutes. Supernatants were 
collected and quantified for protein content using BIO RAD’s DC protein Assay and photometry 
at 690nm. 
 
5.2.8 SDS PAGE and Western blotting 
20 µg of protein were reduced in NuPAGE LDS Sample Buffer and Sample reducing agent by 
boiling at 95°C for 5 minutes. Samples were loaded on a NuPage 4 – 12% Bis-Tris gradient gel 
and put in MES SDS running buffer. The gel ran at a constant voltage of 150V for approx. one 
hour. After proteins were separated by size, they were blotted on a PVDF or nitrocellulose 
membrane using transfer Buffer containing 15% methanol. Therefore, a constant voltage of 
100V was applied for 45 – 60 minutes, depending on the protein size of interest. After blotting 
the membrane was incubated in blocking buffer for 90 minutes followed by primary antibody 
incubation at 4°C overnight. Antibodies were used in BSA blocking buffer. 
 
The next day membranes were washed three times for 10 minutes in washing buffer on a 
rocker followed by secondary antibody incubation for one hour. Antibodies were diluted in 
BSA blocking buffer. 
 
Thereupon membranes were washed as stated above. 
Proteins were detected using ECL Western Blotting Detection Reagent and 
chemiluminescence Hyperfilm and an automated developing machine following 
manufacturer’s protocol. 
Actin was generally used as a loading control and pan ERK during phospho ERK detection. 
 
5.2.9 Flow cytometry 
Quantification of apoptotic cells: 
SCC13 cells, transfected with miR-181a mimics, were stained using BD Pharmigen’s FITC 
Annexin V Apoptosis Detection Kit I following the manufacturer’s protocol. UVB-irradiated 
cells were used as a positive control and to adjust proper gate setup. Another subset of cells 
was boiled at 96°C for 5 minutes, representing dead cells and serving as an additional gating 
aide. Measurements were performed on a FACSCanto device. Data were analyzed with FlowJo 
software. 
 
Quantification of CYFIP1 expressing cells: 
Prior to staining, SCC 13 cells were fixed with 1% PFA and permeabilized with 1% saponin. For 
the assessment of the protein expression the following antibodies were used: unconjugated 
polyclonal rabbit anti-human CYFIP1 in the dilution 1:100 with FITC conjugated secondary 
swine anti-rabbit antibody, diluted 1:25. Measurements were performed on a FACSCanto 
device. Data were analyzed with FlowJo software. 
 
5.2.10 Transfection 
Transient transfection of siRNAs, miRNA mimics and miRNA inhibitors was performed using 
Interferin. Lager constructs, like DNA plasmids, were transfected by the aid of GeneCarrier 1. 
All transfections were carried out for 48 hours and following the manufacturer’s protocol. In 
short, Cells were seeded 24 hours prior to transfection followed by medium change. The 
according transfection reagent was diluted in basal medium (cell culture medium without FCS 
or other supplements) after nucleotides were added. After 30 minutes of incubation the 
solution was added drop wise to the cells and incubated at 37°C for 48 hours. 
 
5.2.11 Transduction 
Lentiviral particles were either obtained by Sigma Aldrich (Mission Lentiviral particles) or 
produced using the psPAX2 Second Generation System in HEK293T cells following a modified 
protocol based on Barde et al [236]. psPAX2, pMD2.G and the construct to be packed were 
transfected into HEK293T cells in a weight ratio of 1:3:4. After 24 hours the transfection 
medium was swapped with DMEM 10% FCS for three consecutive days. All supernatants were 
collected and stored at 4°C in the dark. At the end of the production phase, all supernatants 
were pooled following slow centrifugation at 500xg to remove detached cells and cell debris. 
In order to pellet the lentiviral particles, the supernatant was ultra-centrifuged at 16°C, 
50,000xg for 120 minutes. After resuspending pellets in 500 µl DMEM 10% FCS, viral stocks 
could be stored at -80°C or directly used. For the transduction procedure SCC13 cells were 
seeded at ~30% confluence into 10cm petri dishes 24 hours prior to the experiment. Medium 
was swapped with DMEM 10% FCS containing 8μg/ml of hexadimethrine bromide and a 500 
µl stock of resuspended lentiviral particles and incubated overnight at 37°C. The next day, 
medium was swapped with regular DMEM 10% FCS. After another 24 hours, the selection 
process was initiated using puromycin selection medium (DMEM 10% FCS supplemented with 
5µM puromycin). The selection medium was changed daily until successfully transduced cells 
formed clones measuring approx. 3mm in diameter. By the use of cloning cylinders in 
combination with high viscosity Vaseline the cell clones were isolated, detached and 
transferred into 96 well plates. Cell clones were expanded and tested for functionality via 
qPCR or Western Blot. 
 
5.2.12 In vivo tumor xenograft 
All experiments were performed according to guidelines of the approved “Bundesamt für 
Lebensmittelsicherheit und Veterinärwesen - BLV” protocol. Female nude mice (4–6 weeks 
old) were ordered from Harlan Laboratories Inc. and acclimatized to the mouse facility for 10 
days. HaCaT kd miR-181a, SCC13 Tet-On miR-181a or the according number of control cells 
were suspended in PBS to a final concentration of 4 × 107 or 1 × 107 per ml, respectively. 100 
µl of the cell suspension were injected subcutaneously in one or both flanks using 0.5ml insulin 
syringes. Doxycycline for the Tet-On experiment was administered via food pellets 
(200mg/kg). The tumors were measured three times a week using a caliper. The tumor volume 
was calculated using the formula volume, V = L × W2/2, where L corresponded to long diameter 
and W to short diameter [237]. In parallel, mice where weighted once per week using a 
standard laboratory scale. The experiment was terminated after reaching significance. Single 
mice were euthanatized in case one or more of the termination criteria were fulfilled, such as 
tumor mass greater than 1cm3, ulcerating tumors, severe weight loss or lack of fight/flee 
instincts. Tumors of dead mice were dissected, whereat RNA was isolated from one half and 
hematoxylin-eosin (H&E) slides were produced from the other part. 
 
5.2.13 Histology 
5.2.13.1 Hematoxylin and eosin staining 
Excised tumors from terminated mice were fixed in 4% formalin, followed by dehydration and 
embedding in paraffin. Seven micron sections were cut, deparafinized, dehydrated and 
stained with H&E [238]. High resolution pictures were taken with an Aperio ScanScope. 
 
5.2.13.2 Immunodetection 
Conditions for immunoblotting were as described previously [239]. The following antibodies 
were used: actin (sc-1616), p21 (sc-6246), Notch1 (sc-6014) (Santa Cruz), involucrin (Abcam, 
ab68) loricrin, filaggrin, Hes1 (AB5702) and CYFIP1 (07-531) (Millipore). 
Immunohistochemistry was performed as reported previously [240]. Briefly: 3- to 5-μm 
adjacent sections of formalin-fixed paraffin-embedded tissue arranged in a tissue microarray 
were used. The deparaffinized sections were heated in a 100-W household microwave oven 
at maximum power for three times 5 minutes each in 10 mmol/L citric acid for antigen 
retrieval. Primary antibody was applied for 16 hours at 4°C. Secondary staining was performed 
using the DAKO APAAP kit. The immunohistochemistry results were quantified by two 
independent persons. The signal intensity was graded into arbitrary units from 1 point which 
referred to no signal up to 10 points which referred to a very strong signal. The samples were 
analyzed for the total signal intensity that included the signal from all the epidermis layers.   
 
5.2.14 Cloning 
Construction of DNA plasmids and vectors was done using NEB’s Gibson Assembly Kit 
following the manufacturer’s protocol. In short, the target plasmid was cracked via restriction 
enzyme digestion, followed by size separation on a 1-2% agarose gel. The according bands 
were identified by UV illumination and cut out, followed by DNA cleanup and zipping in order 
to prevent religation. Synthesized DNA fragments had to be equipped with 20 – 30 nucleotide 
overhangs exactly matching the sequence next to the insertion sites within the destination 
plasmid. Digested plasmid and DNA fragments in a stochastic ratio of 1:3 had to be incubated 
together with Gibson Assembly Enzyme and Buffer at 37°C for one hour. Subsequently, the 
product could be transformed into competent cells on ice for 10 minutes followed by plating 
on agar plates and overnight 37°C incubation. Successfully ligated constructs gave rise to 
bacterial colonies under antibiotic selection which were expanded in liquid LB broth followed 
by DNA plasmid extraction using mini/maxi prep kits. 
 
5.2.14.1 Construction of Tet-On miRNA over expression plasmids 
miR-181a hair pin sequence plus 210 base pairs of the flanking region in either direction and 
the according Gibson Assembly adapters were synthesized (Integrated DNA Technologies). 
The inserts were cloned into digested pTRIPZ (EcoRI and XhoI) using NEB’s Gibson Assembly 
Kit and following manufacturer’s protocol. 
 
5.2.14.2 Generation of cell lines stably overexpressing KRAS 
pUNO KRAS over expression plasmid (Invovogen) was transfected into cell lines as described 
above. Positive cells were selected using Blasticidine (5µM). Clones were picked, expanded 
and checked for stable KRAS expression via Western blotting. For KRAS 3’UTR experiments 
pGL4.75-KRAS LCS6m was used as a KRAS 3’UTR donor and sub cloned into pUNO KRAS with 
NheI-HF and T4 DNA ligase. Three miR-181a binding sites were mutated using Phusion-HF 
polymerase for mutagenesis and custom designed mutagenesis primers. 
 
 
5.2.15 ChIP 
Human epidermis was separated from the underlying dermis by a brief heat treatment and 
was minced finely in ice-cold PBS. Confluent primary keratinocytes as well as tissue samples 
were then cross-linked with 37% formaldehyde to a final concentration of 1% followed by the 
addition of glycine (final concentration 125 mM). After cross-linking, tissues were washed 
twice with 10 ml PBS with protease inhibitor. Tissue pellets were processed for ChIP assays as 
previously described using the rabbit anti-Notch1 antibody in parallel with affinity-purified 
non-immune IgGs [69]. Primers used for real-time PCR of the two regions of the human CYFIP1 
promoter and for a region of human HES1 can be found in the materials section. 
 
5.2.16 Luciferase activity assay 
Human CYFIP1A promoter region was synthetized by Blue Heron Biotech (Bothell, WA) and 
inserted in pGL3-basic between the KpnI and BglII restriction sites (pGL3-CYFIP1A-3kb). SCC13 
cells or primary keratinocytes were co-transfected with 0.5 µg of pGL3-CYFIP1A-3kb, 2 µg of 
the Notch1 expressing plasmid pcDNA3-Notch1 or empty vector as control and 0.05 µg of the 
Renilla internal control plasmid (phRL-TK). As a control of experiment, cells were also in 
parallel co transfected with 0.5 µg of the RBPjk-luc plasmid (Notch reporter plasmid), 2 µg of 
the Notch1 expressing plasmid pcDNA3-Notch1 or empty vector as control (pcDNA3) and 0.05 
µg of phRL-TK. Cells were harvested 30 hours after transfection and assayed for Firefly and 
Renilla luciferase activity with the Dual Luciferase assay reporter kit. Results are expressed as 
relative firefly activity over Renilla luciferase activity. All experiments were performed in 
triplicates. 
 
5.2.17 Invasion assay 
Prior to the assay, cells were incubated for 48 hours at starving conditions with 10 x decreased 
concentration of supplements. The invasion capacity was assessed using 24 well-sized BioCoat 
Matrigel Invasion Chambers with 8 µm pore size. In order to hydrate the matrigel, inserts were 
incubated in basal cell medium for two hours at 37°C. Treated cells were suspended in basal 
medium at a concentration of 1 x105 cells /ml and 500 µl cell suspension was pipetted into the 
inserts. As a chemoattractant, wells of a 24 well plate were filled with 750 µl of full medium. 
After 24 hours, cells were either stained and used for the calculation of invasive capacity or 
mechanically detached from both sides of the PET membrane and assessed for protein 
expression by flow cytometry or Western blotting. 
 
5.2.18 MEK inhibitor 
For MEK inhibition GSK1120212 (Cellagen Technology, #C4112-5) was used at concentrations 
of 500 nmol/L. DMSO was used to prepare stock solutions and also as a control treatment 
during the experiments. 
 
5.2.19 Statistics 
All statistical evaluations were carried out using GraphPad Prism 5.0. The analyses were two-
tailed Student’s t-test of three independent experiments. Several experiments (except for in 
vivo experiments) were carried out three times independently followed by mean and error 
determination. The error bars represent standard deviations (SD). In vivo experiments were 
evaluated using ANOVA with Bonferroni correction where error bars represent standard error 
of the mean (SEM). P-values of < 0.05 were considered significant. 
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6.1.1 Abstract 
Cutaneous squamous cell carcinoma (SCC) is the second most common human skin cancer 
with a rapidly increasing incidence among the Caucasian population. Among the many 
regulators, responsible for cancer progression and growth, microRNAs (miRNA) are generally 
accepted as key players by now. In our current study we found that microRNA-181a (miR-
181a) shows low abundance in SCC compared to normal epidermal skin. In vitro, miRNA 
downregulation in normal primary keratinocytes induced increased proliferation, while in vivo 
miR-181a downregulation in HaCaT normal keratinocytes showed tumor-like growth increase 
up to 50%. Inversely, upregulation of these miRNAs in cancer cells lead to reduced cellular 
proliferation and induction of apoptosis in vitro. An in vivo therapeutic model with induced 
miR-181a expression in SCC13 cancer cells reduced tumor formation in mice by 80%. 
Modulation of miR-181a levels showed an inverse correlation with the proto oncogene KRAS 
both on mRNA and protein level by direct interaction. Knockdown of KRAS mimicked the anti-
proliferative effects of miR-181a overexpression in patient-derived SCC cells and abolished the 
enhanced viability of HaCaT cells following miR-181a knockdown. Furthermore, phospho-ERK 
levels correlated with KRAS levels, suggesting that the observed effects were mediated via the 
MAPK signaling pathway. miR-181a seemed regulated during keratinocyte differentiation 
probably in order to amplify the tumor suppressive character of differentiation. Taken 
together, miR-181a plays a crucial tumor suppressive role in SCC by targeting KRAS and could 
be a promising candidate for a miRNA based therapy. 
  
6.1.2 Introduction 
Cutaneous squamous cell carcinoma (SCC) is the second most common skin malignancy in the 
general population with a rapidly rising incidence among Caucasians. It typically arises from 
intraepithelial lesions like actinic keratosis on sun-damaged skin [241, 242]. Disturbed 
differentiation represents a hallmark of SCC reflected by a diverse pattern of differentiation 
markers like Filaggrin and Involucrin or various keratins [243]. About 50% of all SCCs carry p53 
mutations and a typical UV signature presenting with cyclobutane pyrimidine dimers, making 
UV light a major SCC risk factor [244]. Organ transplant recipients (OTR), however, harbor a 
65 – 250 fold increased SCC incidence compared to the general population due to continued 
immunosuppression [245]. Once SCC occurs, further SCC arising on sun-damaged skin are 
likely. Field-directed treatments like photodynamic therapy, imiquimod or ingenol mebutate 
are available, but all cause considerable inflammation and disfiguration [97, 115]. Here, future 
siRNA or microRNA based agents could prove beneficial by reverting a keratinocyte’s course 
towards regular differentiation and cell death without inflammation. 
 
miRNAs are approximately 20 nucleotide-long non-coding RNA molecules binding to the 3' 
untranslated regions (UTR) of target mRNAs in a sequence-specific manner influencing 
translation and/or stability of the transcripts [246]. miRNA effectively play roles in almost all 
aspects of cancer biology, such as in proliferation, apoptosis, metastasis and angiogenesis 
(reviewed in [247]). A large screen of miRNA expression in SCC singled out miR-181a as 
downregulated in our SCC patient samples. We thus studied expression and functionality of 
miR-181a in primary patient-derived and various cell lines representing normal skin and SCC. 
Our findings indicate a crucial role for miR-181a in regulating keratinocyte proliferation 
mediated by KRAS interaction and MAPK pathway inhibition, prompting us to validate these 
findings in a xenograft mouse model. 
 
  
6.1.3 Results 
miR-181a is downregulated in SCC compared to normal skin 
In order to get a general overview into the miRNA landscape in SCC we extracted total RNA of 
the epidermal fraction of SCC from OTR (n = 8) and immunocompetent patients (n = 7) as well 
as normal skin control samples (n = 5). 
The initial microRNA microarray screen revealed a highly deregulated miRNA pattern of the 
two SCC groups when compared to normal skin. miR-181a showed low abundance among SCC 
confirmed by TaqMan qPCR (Figure 1A). Notably, there was no difference in expression levels 
between OTR and immunocompetent SCC (data not shown). 
 
Low levels of miR-181a result in increased cellular viability in vivo and in vitro 
Decreased cellular presence of miRNAs presumably permits increased activity of their 
downstream targets and might in turn promote tumor formation. For the following functional 
assays, we set up a keratinocyte culture system from patient-derived SCC and normal 
cutaneous primary keratinocytes. In addition, we selected a panel of keratinocyte cell lines 
according to their basal miRNA expression levels (Suppl. S1). Since HaCaT, a cell line derived 
from normal human keratinocytes, and human SCC cell lines SCC13 and A431 exhibit miR-181a 
levels similar to patient samples, these cell lines were considered most suitable for our 
experiments. 
 
Indeed, HaCaT cells harboring a stable miR-181a knockdown (kd miR-181a) and injected 
subcutaneously into nude mice had pronounced cyst formation capability while the respective 
control cells hardly formed a cyst (Figure 1B and Suppl. 3A and B). H&E histological sections of 
the kd miR-181a cysts did not only differ in size, but revealed pathological characteristics 
typical for intraepithelial SCC: Disturbed differentiation with distinct eosinophilic 
hyperkeratosis accompanied by parakeratosis (Figure 1C) akin to human SCC. Control cysts, 
on the other hand, showed relatively inconspicuous keratinocyte differentiation and 
basophilic cornification (Figure 1C). In vitro WST-1 assays confirmed the inverse correlation 
between cellular viability and miR-181a levels; kd miR-181a showed greater values compared 
to control cells (Figure 1D). HaCaT kd miR-181a cells isolated from cysts after the experiments 
endpoint or from in vitro cultures exhibited lower miR-181a levels when compared to control 
cells (Suppl. 3C and 4). On the contrary, knockdown of miR-181a did not induce proliferation 
in primary SCC cells or SCC13 in which miR-181a was already lower, indicating that a 3-5-fold 
reduction in miR-181a was already sufficient to confer the maximum induction of proliferation 
(Figure 1F). 
Due to its simplicity combined with a high degree of sensitivity as well as reliability, WST-1 is 
widely used to investigate differences in cellular proliferation rates. We are well aware that 
WST-1 is reduced in the mitochondria during events happening in the respiratory chain and 
reflects therefore metabolic activity. To evaluate this assay for our needs, we performed a 
WST-1 assay on healthy primary keratinocytes transfected with miR-181a or control inhibitors. 
In parallel all cells were counted at the starting and end point of the assay and normalized to 
control cells. In addition, we performed a BrdU incorporation assay, which represents another 
widely used, but more complex proliferation assay. Since the WST-1 measurement, manual 
cell counting and BrdU incorporation assay delivered comparable results, we concluded that 
mitochondrial activity adequately reflects cellular proliferation rates in keratinocytes (Suppl. 
2). For the sake of correct scientific terminology however, we will stick to the term “viability” 
in our graphs. 
 
Figure 1: Low abundance of miR-181a is found in patient derived SCC specimen compared to 
normal skin and down regulation of miR-181a leads to increased viability in healthy 
keratinocytes 
(A) Total RNA was isolated from patient derived SCC or normal skin biopsies (epidermal part). miR-
181a levels were determined via TaqMan qPCR. (B) HaCaT knock down (kd) miR-181a or control cells 
were injected subcutaneously into nude mice. Over all significance of the time course experiment was 
calculated using two way Anova and Bonferroni correction. A Student’s t-Test was performed at the end 
point (day 24) (Suppl. 3B). (C) H&E sections of cysts. Black bar = 100µm. (D) Viability of HaCaT kd miR-
181a cells in vitro. (E + F) Cells were transfected with miR-181a inhibitors for 48 hours. For in vitro 
viability assays cells were seeded into 96 well plates and incubated for 96 hours followed by WST-1 
assay. P values for in vitro assays were Calculated via Student’s T test. SCC = cultured SCC cells 
derived from patient samples, PK = cultured healthy keratinocytes derived from patient samples. 
 
 
High levels of miR-181a result in decelerated cellular viability in vivo and in vitro 
Following our observation of an inverse correlation between miR-181a levels and cellular 
viability, we were speculating that an upregulation of miR-181a would lead to decreased 
cellular viability in cancer cells. Therefore, we established a tetracycline-inducible miR-181a 
over expression model based on pTRIPZ Tet-On plasmid and SCC13 cells (Tet-On miR-181a). 
When injected subcutaneously into nude mice, control cells formed rapidly growing tumors, 
reaching termination criteria (tumor size > 1cm3 and/or ulceration) relatively early. miR-181a 
over expressing cells, on the other hand, grew slower and reach termination criteria at later 
time points (Figure 2A and Suppl. 5A - C). 
In addition, Tet-On miR-181a showed decreased viability when doxycycline was added to the 
medium (Figure 2B). Maintained miR-181a expression in tumors with Tet-On miR-181a and in 
vitro cell cultures confirmed a robust miRNA induction by doxycycline activation (Suppl. 5D 
and Suppl. 6A). Fittingly, transfection of synthetic miRNAs (miRNA mimics) into cancer cells or 
stable miR-181a knock in led to decreased cellular viability accompanied by cell rounding and 
detachment (Figure 2D and supplementary 7B). FACS analyses as well as immunoblotting 
revealed a high number of apoptotic cells, identified by AnnexinV+/7AAD- staining and 
Caspase-3 cleavage respectively, compared to the control group transfected with control 
miRNA (Suppl. 7A). Interestingly, healthy primary keratinocytes and HaCaT cells were 
vulnerable to miR-181a upregulation to a certain degree as well (Figure 2E). An additional 
conformation was done in SCC13 cells transduced with a stable miR-181a over expression 
plasmid (ki miR-181a). As expected, these cells exhibited lower viability compared to control 
cells, while their miR-181a levels were strongly upregulated (Figure 2C and Suppl. 6B). 
 
 
Figure 2: Up regulation of miR-181a leads to decreased viability in cancer cells 
(A) SCC13 was transduced with pTRIPZ for inducible miRNA overexpression (SCC13 Tet-ON miR-
181a) and injected subcutaneously into nude mice. Doxycycline (200 mg/kg) was administered via food 
pellets. Over all significance of the time course experiment was calculated using two way Anova and 
Bonferroni correction.  (B) SCC13 Tet-On miR-181a were seeded into 96 well plates and exposed to 
doxycycline during the course of the experiment. Cells were transduced with pLKO.miRNA (ki miR-
181a) for stable miRNA overexpression (C) or transfected with miRNA mimics for 48 hours (D + E). 
Cells were seeded into 96 well plates and incubated for 96 hours followed by WST-1 viability assay. P 
values for in vitro assays were calculated via Student’s t-Test. SCC = cultured SCC cells derived from 
patient samples, PK = cultured healthy keratinocytes derived from patient samples. 
 
 
KRAS is a direct target of miR-181a 
Next we aimed to unravel the molecular mechanism laying behind miR-181a’s negative effect 
on cellular viability. The proto-oncogene KRAS plays a critical role in a variety of malignancies 
and the interplay of miR-181a and KRAS has been described in other epithelial cancers [248]. 
Healthy cells with repressed miR-181a, either by transfection of miRNA inhibitors (Figure 3A) 
or by stable knock down (Figure 3B), showed higher KRAS protein and mRNA levels. SCC13 
cells, on the other hand, exhibited lower KRAS levels when miR-181a was upregulated either 
by transfection of miRNA mimics (Figure 3C) or by stable miR-181a over expression (Figure 
3D). 
miRNAs are interacting with the 3’UTRs of their target mRNAs in a sequence-specific manner 
and are thereby interfering in the process of protein translation. In our approach we took 
advantage of the KRAS overexpression plasmid pUNO KRAS and cloned the according 3’UTR 
upstream of the start codon. A 3’UTR containing mutated miR-181a binding sites served as a 
control (Figure 3E). HaCaT cells stably transfected with these plasmids were characterized by 
elevated KRAS protein levels. However, only the cells containing the wild type KRAS 3’UTR 
were vulnerable to miR-181a mimic transfection resulting in reduced KRAS protein translation 
and thus in reduced cellular viability (Figure 3F). The same KRAS 3’UTR system transfected into 
HEK293T cells showed a similar picture. Cells harboring the wild type KRAS ‘3UTR had reduced 
KRAS protein after miR-181a mimics treatment while cells harboring a mutated 3’UTR were 
less responsive to miR-181a mimics (Suppl. 8). 
 
 
 
 
 
Figure 3: miR-181a targets KRAS directly 
Cells were transfected with miRNA mimics (A) or inhibitors (C) for 48 hours or transduced with 
pLKO.miRNA.inhibitor / pLKO.miRNA  (kd miR-181a / ki miR-181a) for stable miRNA modulation (B and 
D). Cells were lysed and mRNA or protein level analyses were performed using SYBR green qPCR or 
Western Blot respectively. (F) HaCaT cells were stably transfected with the indicated pUNO KRAS over 
expression plasmids in selection medium. Selected clones were transfected with miR-181a mimics for 
48 hours following by WST-1 assay and Western Blot. (E) The panel in the left illustrates the three main 
miR-181a binding sites in KRAS 3’UTR and the according mutations. Student’s t-Test was used to 
calculate P values. 
  
miR-181a mediates its tumor-suppressive role through KRAS signaling via the MAPK 
pathway 
Following the observation that miR-181a in keratinocytes correlated negatively with KRAS 
expression and with cellular viability, we were interested in a functional role of KRAS in 
keratinocytes. First we stably overexpressed KRAS in HaCaT using the pUNO KRAS plasmid 
(HaCaT pUNO KRAS) and performed a WST-1 assay. The result revealed that KRAS, when 
overexpressed, was able to boost viability in HaCaT similarly as a miR-181a knock down did. 
Notably, MAPK signaling was activated during this process (Figure 4A). Aiming to address the 
question whether there is a direct functional connection between miR-181a and KRAS we 
transfected HaCaT kd miR-181a with siRNA against KRAS or control siRNA. As expected, HaCaT 
cells harboring a stable miR-181a knock-down proliferated faster when only transfected with 
control siRNA, similarly as observed before. Reducing miR-181a’s target KRAS, using siRNA, 
abolished this effect (Figure 4B). Notably, this effect was most likely not caused by siRNA off 
target effects, because two different siRNA sequences lead to similar results (data not shown). 
As mentioned before, MAPK signaling was activated as a result of KRAS overexpression. 
Therefore, we speculated that KRAS uses the MAPK signaling pathway to mediate its 
oncogenic signals in the cell. Initially, we treated HaCaT cells using epidermal growth factor 
(EGF) to trigger MAPK signaling, resulting in enhanced proliferation rates similarly as observed 
in HaCaT kd miR-181a (Figure 4C). Furthermore, we used HaCaT kd miR-181a which exhibited 
increased viability compared to control. This difference was abolished upon treatment with a 
MEK inhibitor (Figure 4D). 
Suppression of KRAS by siRNA knock down, on the other hand, decreased viability in primary 
patient-derived SCC cells (SCC) similarly as miR-181a overexpression did (Figure 4E). 
Additionally, overexpressed KRAS rescued miR-181a mimics-induced effects in SCC13 to a 
large part (Figure 4F).  
 
 
 
Figure 4: miR-181a mediates its tumor suppressive role through KRAS which signals via the 
MAPK pathway 
Cells were transfected with the indicated siRNAs or miRNA mimics (A). In addition to siRNA/mimics the 
cells were transduced with the indicated plasmids (A - F). All transfections were carried out for 48 hours. 
A subset of the cells was seeded into 96 well plates, followed by WST-1 assay, while RNA and protein 
was isolated from the left overs. Protein and mRNA levels were determined by Western Blot or SYBR 
Green qPCR respectively. Student’s t-Test was used to calculate P values. kd = knock down, SCC = 
cultured SCC cells derived from patient samples 
 
 
miR-181a levels increased during keratinocyte differentiation 
Since SCC can be characterized by disturbed differentiation, we speculated that miR-181a 
expression might be regulated during this process. 
First we differentiated primary healthy keratinocytes by keeping them cultured confluent for 
a week. Direct cell-cell contact is required for NOTCH1 activation which subsequently initiates 
the differentiation cascade. Comparing these matured cells with proliferating ones revealed 
increased miR-181a levels accompanied by clearly elevated differentiation markers in the 
differentiated subset (Suppl. 9A). SCC13 cells which cannot differentiate due to NOTCH1 
defects, regained the ability to mature when Notch1 was inducibly knocked in. During 
differentiation miR-181a levels went up (Suppl. 9C and Suppl. 10). Induction of keratinocyte 
differentiation by adding Ca2+ to the medium or by UVA irradiation lead to similar results 
(Suppl. 9B + D). 
 
 
  
6.1.4 Discussion 
In our study we have identified miR-181a as a critical factor in SCC progression. The published 
body of evidence on miR-181a mainly shows a carcinogenic role for miR-181a such as in [249-
252], making miR-181a a so-called `oncomir´. A smaller part of the data on miR-181a, 
however, identifies miR-181a as a tumor suppressor in some cancers of the brain and the 
hematopoietic lineage [253-255]. This tumor suppression seems mainly to impact invasion 
and metastasis in tumors of the liver [256], salivary glands [257] and the ovary [258], and to a 
smaller part to impact proliferation such as in non-small cell lung cancer (NSCLC) [259] and 
acute myeloid leukemia [260]. These discrepancies on the function of miR-181a in different 
tumors, highlight miR-181a’s context specificity depending on the environment. Our data 
show a tumor-suppressive role of miR-181a in the context of keratinocyte cancer with an 
impact on SCC proliferation.  Contrary to miR-181a knockdown, reestablishing miR-181a levels 
in SCC attenuates cancer both in vivo and in vitro. Showing functionality beyond epithelial 
cancers, miR181a overexpression suppresses cell growth in xenograft tumors in chronic 
myelogenous leukemia [261] and large B-cell lymphoma [262]. The effect size on SCC in our 
study seems larger, suggesting therapeutic potential for miR-181a against SCC. 
 
Based on known interaction of miR181a with KRAS [263], our study identified a direct 
interaction of the proto-oncogene KRAS with miR-181a in SCC confirming findings from other 
organ tumors [248, 259]. While this direct interaction has already been demonstrated using a 
dual luciferase assay [248, 260], we document this interaction in our system in a novel fashion 
by mutating the 3’-UTR of KRAS coupled with actual KRAS expression. This system allowed us 
to perceive the miR-181a-KRAS interaction above the background of endogenous KRAS 
expression. We thus support the previously found interaction between miR-181a and KRAS 
3’UTR and directly link its main functional consequence to SCC, namely a change in cellular 
viability. The mechanism of KRAS in keratinocytes, however, is only sketchily described. Our 
data confirm that the well-known downstream mediators of KRAS function are found in the 
MAP kinase pathway [86, 257]. While KRAS acts as an oncogenic driver mainly by activating 
mutations [264-266], posttranscriptional control of KRAS by miRNA deregulation has been 
identified repeatedly [92, 93, 267, 268]. Our data suggest that such posttranscriptional control 
of KRAS by miR-181a may be critical in SCC development.  
 
Differentiation is a key mechanism in cell control, maintaining homeostasis and preventing 
cancer development [60, 269]. Our data shows that differentiation in keratinocytes at large 
increases miR-181a expression, suggesting a role for miR-181a in a common pathway of 
differentiation, and that removing miR-181a is critical for the transition of keratinocytes into 
SCC. A similar weight has been reported in keratinocytes for miR-203 and miR-24 [270-272], 
underlining the impact of miRNAs in differentiation [273-275]. We thus believe that miR-181a 
is an important mediator of differentiation in keratinocytes. In summary, our data singles out 
miR-181a as a critical determinant in keratinocyte differentiation and control of SCC 
development. Manipulating miR-181a in vivo demonstrates the potential of miR-181a as a 
potential therapeutic miRNA in SCC. 
 
6.1.5 Supplementary data 
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Supplementary Figure 1: Endogenous miR-181a levels of cell lines used in the present study 
Total RNA was isolated and transcribed into cDNA. miR-181a levels of various cell lines were 
determined via TaqMan qPCR. PK = cultured healthy keratinocytes derived from patient samples, SCC 
= SCC cells derived from patient samples. 
 
 
 
Supplementary Figure 2: WST-1 viability assay represents keratinocyte proliferation rates 
Primary keratinocytes and HaCaT cells were transfected with miR-181a inhibitors or control sequence 
and seeded into Petri dishes. Cells were incubated for 96 hours and manually counted at the 
experiment’s end point. WST-1 and BrdU assays were performed in 96 well plates after 96 hours of 
incubation time. Statistical analysis was performed using Student’s t-Test. PK = cultured healthy 
keratinocytes derived from patient samples. 
 
 
Supplementary Figure 3: miR-181a knock down promotes cyst formation in vivo 
(A) HaCaT knock down (kd) miR-181a cells were injected subcutaneously into nude mice. Arrows in the 
upper panels highlight cysts or rudimental cysts. Lower panels show H&E stainings of the cysts. Length 
of black bars = 1mm. (B) Cyst volumes at the experiment’s end point (day 24). (C) miR-181a levels of 
cysts isolated after mice were terminated. Whole RNA was isolated and transcribed into cDNA followed 
by TaqMan qPCR. Statistics were performed using Student’s t-Test and Welch’s correction. kd = knock 
down. 
 
 
 
Supplementary Figure 4: miR-181a levels of HaCaT cells harboring stable miR-181a knock down. 
Whole RNA was isolated and transcribed into cDNA. miR-181a levels of HaCaT kd miR-181a were 
determined via TaqMan qPCR. Statistics were performed using Student’s t-Test. kd = knock down. 
 
 
Supplementary Figure 5: Up regulation of miR-181a leads to decreased tumor growth in vivo 
(A) SCC13 Tet-ON miR-181a were injected subcutaneously into nude mice. Doxycycline (200 mg/kg) 
was administered via food pellets. (B) Tumor volumes at the statistical endpoint of the experiment (day 
21). (C) Kaplan-Meier survival curve. (D) miR-181a levels of tumors isolated after mice were terminated. 
Whole RNA was isolated and transcribed into cDNA follow by TaqMan qPCR. Statistics were performed 
using Student’s t-Test and Welch’s correction. 
 
 
 
Supplementary Figure 6: miR-181a levels of SCC13 with artificial miR-181a up regulation. 
(A) SCC13 Tet-On miR-181a were incubated with 500nM doxycycline for 48 hours. (B) SCC13 stably 
over expressing miR-181a. Whole RNA was isolated and transcribed into cDNA followed by TaqMan 
qPCR. Statistics were performed using Student’s t-Test. ki = knock in. 
 
 
 
Supplementary Figure 7: miR-181a up regulation induces apoptosis in SCC13 
(A) SCC13 cells were transfected with miR-181a mimics for 48 hours. One fraction was stained for 7AAD 
and AnnexinV following FACS analysis. Cells were irradiated with 0.06 J/cm2 UVB for gating setup and 
served as a positive control. Protein from the other fraction was isolated and used for cleaved caspase 
3 determination via Western blotting. (B). Cells were transfected with miR-181a mimics for 48 hours and 
seeded into petri dishes. 96 hours post transfection pictures were taken. 
 
 
Supplementary Figure 8: miR-181a targets KRAS directly 
Indicated pUNO KRAS over expression plasmids and miR-181a mimics were transfected 
simultaneously into HEK293T cells for 48 hours. Protein was extracted followed by Western Blot. The 
panel in the left illustrates the three main miR-181a binding sites in KRAS 3’UTR and the according 
mutations. 
 
 
Supplementary Figure 9: miR-181a levels are increased during keratinocyte differentiation 
Cells were differentiated by keeping them in a confluent state for a week (A), by Ca2+ exposure (B), by 
transducing an inducible NOTCH1 plasmid (C) or by exposing them to 25 joule UVA irradiation. Protein 
and mRNA levels were determined by Western Blot or qPCR respectively. Student’s t-Test was used to 
calculate P values. 
 
 
Supplementary Figure 10: SCC13 cells harboring a tetracycline inducible Notch1 construct  
SCC13 pIND20 Notch1 were incubated with 500nM doxycycline for 48 hours. Whole RNA was isolated 
and transcribed into cDNA followed by TaqMan qPCR. qPCR primers were designed to target the 
expression sequence (intra-cellular domain of Notch1) of pIND20 Notch1. 
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6.2.1 Abstract 
Squamous cell carcinoma of the skin (SCC) represents one of the most common cancers in the 
general population and is associated with a substantial risk of metastasis. Previous work 
uncovered the functional role of CYFIP1 in epithelial tumors as an invasion inhibitor. It was 
down-regulated in some cancers and correlated with the metastatic properties of these 
malignant cells. We investigated its role and expression mechanisms in SCC.  
We analyzed the expression of CYFIP1 in patient derived SCC, primary keratinocytes and SCC 
cell lines, and correlated it to the differentiation and NOTCH1 levels. We analyzed the effects 
of NOTCH1 manipulation on CYFIP1 expression and confirmed the biding of NOTCH1 to the 
CYFIP1 promoter.  
CYFIP1 expression was down-regulated in SCC and correlated inversely with histological 
differentiation of tumors. As keratinocyte differentiation depends on Notch1 signaling, we 
investigated the influence of NOTCH1 on CYFIP1 expression. CYFIP1 mRNA was highly 
increased in human NOTCH1-overexpressing keratinocytes. Further manipulation of the 
Notch1 pathway in keratinocytes impacted CYFIP1 levels and chromatin immunoprecipitation 
assay confirmed the direct binding of NOTCH1 transcription factor to the CYFIP1 promoter. 
CYFIP1 may be a link between loss of differentiation and invasive potential in malignant 
keratinocytes of cutaneous squamous cell carcinoma.   
6.2.2 Introduction 
Squamous cell carcinoma of the skin (SCC) belongs to the most common cancers in the world 
and it is the second most common skin malignancy in the general population [276]. It develops 
from atypical keratinocytes within sun-damaged epidermis, clinically visible as actinic 
keratosis or Bowen’s disease, both considered non-invasive forms of SCC [277, 278]. Within 
the general population, about 1% of affected patients annually develop invasive SCC [37]. 
Unlike basal cell carcinoma – the most common skin malignancy - cutaneous squamous-cell 
carcinoma is associated with a substantial risk of metastasis [37]. The overall five-year rate of 
SCC metastasis is up to 5 percent [127, 279, 280]. The risk of recurrence or metastasis is related 
to the tumor size, location, depth of invasion as well as to histological differentiation [37, 280]. 
In the study by Rowe et al., poorly differentiated squamous cell carcinomas recurred at a rate 
of 28.6 percent and the five-year rate of cure after treatment was 61.5 percent, while in 
contrast well-differentiated tumors had a local-recurrence rate of 1.6 percent with a five-year 
rate of cure of 94.6 percent. In the study of Schmults et all tumor diameter of at least 2 cm, 
invasion beyond fat, poor differentiation, perineural invasion, and ear, temple, or anogenital 
location were risk factors associated with poor outcomes. Other studies have also shown that 
histological differentiation of tumors strongly correlates inversely with the metastasis rate, 
where poorly-differentiated SCC behaves most aggressively [281, 282]. 
 
Notch signaling is an important form of intracellular communication with a key role in cell-fate 
determination and differentiation [71]. In keratinocytes it induces differentiation and 
suppresses tumor development [283]. Its deletion in keratinocytes is sufficient to enhance 
susceptibility to skin cancer formation [239, 284] and loss of its dermal function contributes 
to field cancerization with development of intraepithelial and invasive SCC [16]. Notch1 is a 
trans-membrane receptor that is activated by ligand binding and proteolytic cleavage, with 
release of the intracellular domain [64]. The activated Notch cytoplasmic domain translocates 
to the nucleus, where it associates with the DNA-binding protein CSL and an ancillary protein, 
MamL1 or related family members [285, 286], forming a complex that is required for CSL-
dependent transcription. Among others the best characterized targets of NOTCH1 are HES1, 
p21 and IRF6 [68, 72, 287]. The molecular mechanisms downstream of Notch activation that 
elicit differentiation remain elusive. 
Previous work of Silva et al. described CYFIP1 as a novel putative invasion suppressor in a 
variety of epithelial cancers [147]. CYFIP1 is a RAC1-interacting protein [288] which transmits 
signals from RAC1 to the Arp2/3 complex by modulating the activity of the WASP family 
members, WAVE1‐3, within the WAVE complex. WAVE-mediated activation of Arp2/3 induces 
the nucleation of G-actin to form a membrane protrusion, called lamellipodium, at the leading 
edges of cells growing in classical two-dimensional cultures [142, 289, 290]. It was shown that 
CYFIP1 is commonly deleted in epithelial colon, breast or lung cancers. Reduced expression of 
CYFIP1 was also observed during invasion of these tumors and was associated with a poor 
prognosis. CYFIP1-mediated depletion of WAVE function reduced epithelial adhesion and led 
to disorganization of tissue architecture [147].  
 
In the present work, we show that CYFIP1 is a direct NOTCH1 target in keratinocytes. In this 
context Notch1 is an indirect inhibitor of cell invasion. These findings are of high clinical 
significance, as they suggest a rationale for the relationship between squamous cell carcinoma 
differentiation status and its invasive potential.  
 
  
6.2.3 Results 
CYFIP1 is down-regulated in cutaneous SCC 
Decreased expression of CYFIP1 has been reported in some cancers, such as colon breast or 
bladder cancer [147].The mRNA expression analysis in epidermis from cutaneous SCC samples 
showed reduced mRNA expression in tumors compared to the epidermis of normal skin (Fig 
1a; normal epidermis: mean 0.011, SD ± 0.0059; SCC: mean 0.0069, SD ± 0.0027; p = 0.034). 
This difference was further confirmed by immunohistochemistry on 240 samples of SCC 
samples. CYFIP1 expression was relatively high in normal skin, decreased in in-situ SCC and 
even more so in invasive tumors (Fig 1b, for representative staining see Fig 1c). Interestingly, 
CYFIP1 expression was higher in the upper layers of the epidermis, typically layers with 
advanced differentiation, whereas the cells of the basal layer were mostly negative for CYFIP1. 
Since these basal cells show the lowest differentiation this finding suggests a relationship 
between keratinocyte differentiation and CYFIP1 expression. 
 
Further analysis of the invasive SCC demonstrated differential expression of CYFIP1 after 
stratifying for histological differentiation status. Well-differentiated SCC showed a relatively 
high CYFIP1 expression, which decreased in parallel with differentiation, i.e. with moderate 
expression in moderately differentiated tumors and low expression in poorly differentiated 
tumors (Fig 1d, for representative staining of the well, moderately and poorly differentiated 
SCCs see Fig 1e).  
 
CYFIP1 expression was next assessed in cultured normal human keratinocytes (HKCs) and in 
established human squamous cell carcinoma cell lines derived from skin: SCC12, SCC13 and 
A431. Consistent with the analysis in human SCC samples, SCC12, SCC13 and A431 cell lines 
demonstrated a similarly decreased expression of CYFIP1 on both mRNA as well as on protein 
level (Figure 1f and 1g). Consistent with the findings described above, the expression of CYFIP1 
as well as of the keratinocyte differentiation markers involucrin, filaggrin and loricrin 
increased in cultured HKCs upon induction of differentiation by growth to confluence. This up-
regulation was observed at both the mRNA and protein levels (Figure 1h and 1i). 
 
 
Fig 1. CYFIP1 expression differs between normal keratinocytes and SCC cells. (a) CYFIP1 mRNA 
expression was measured in epidermis derived from normal skin (n=9) and from patients SCC (n=30) 
samples. The RT-PCR demonstrated significant decrease of CYFIP1 mRNA expression in the tumor 
samples *p<0.05. (b) CYFIP1 protein expression in clinical samples was detected by 
immunohistochemistry which was performed on tissue microarray composed of 11 normal skin samples, 
46 in-situ SCCs, and 240 invasive SCCs. The analysis revealed significant protein expression 
differences between all three groups of samples. Keratinocytes in the normal skin show high expression 
of CYFIP1, which is then decreased in in-situ SCC and even lower in invasive SCC *p<0.05, **p<0.01, 
***p<0.001. The representative staining of normal skin, in-situ and invasive SCC are shown in the 
section c. (d) among the invasive SCC the expression levels of CYFIP1 were related to the histological 
differentiation of the tumors. Well differentiated SCC showed relatively high expression of CYFIP1, 
which decreased with the loss of differentiation, so that the lowest expression was observed in poorly 
differentiated SCC. Figure 1e shows the representative staining of well, moderately and poorly 
differentiated SCC, *p<0.05, **p<0.01, ***p<0.001. (f) CYFIP1 mRNA expression has been compared 
between normal human keratinocytes (HKC) and two squamous cell carcinoma cell lines: SCC12, 
SCC13 and A431. At the time of the experiment the cells were at about 70% of confluence. The CYFIP1 
mRNA levels were significantly decreased in the cancer cell lines as compared to normal keratinocytes. 
(g) Similarly to mRNA levels, CYFIP1 protein levels were significantly lower in the cancer cell lines, as 
compared to normal human keratinocytes.  CYFIP1 expression in normal keratinocytes depends on their 
differentiation status. CYFIP1 mRNA (h) and protein (i) are expressed in significantly higher amount in 
differentiated as compared to growing keratinocytes. Cells were at 50% confluence (growing cells), or 
100% confluence for 4 days. After this time total RNA and protein were extracted and RT-PCR and WB 
performed respectively.  
 
CYFIP1 gene expression is under direct positive Notch1 control in keratinocytes 
Notch signaling promotes commitment of keratinocytes towards differentiation and thus 
prevents development of skin cancer [283]. The immunohistochemical analysis of human SCC 
showed coincidentally increased expression of the NOTCH1 and CYFIP1 proteins in upper 
layers of the epidermis, and differentiated keratinocytes (Figure 2a). The statistical analysis 
showed a moderate correlation between the immunoreactivity of these two proteins 
(correlation coefficient r = 0.5; p < 0.0001) (Figure 2b).  
To assess whether CYFIP1 expression is under the control of NOTCH1 signaling pathway, SCC13 
cells, previously reported as expressing low levels of NOTCH1 [239], were stably transfected 
with a retrovirus overexpressing constitutive active form of NOTCH1. As shown in Figure 2c 
and 2d, expression of NOTCH1 led to an induction of CYFIP1 expression on both RNA and 
protein levels.  
These results were further confirmed using SCC13 cells stably transduced with an inducible 
retroviral vector expressing a flag-tagged activated Notch1 protein fused to the human 
estrogen receptor (SCC13Nert). Conditional NOTCH1 expression by 4-hydroxytamoxifen 
resulted in a substantial induction of CYFIP1 (Fig 2e and 2g) in parallel with HES1 (Figure 2f and 
2g), a well-known direct target of NOTCH1 [291]. 
 
 
Fig 2. CYFIP1 is induced during keratinocyte differentiation through a Notch-dependent 
mechanism. 
(a) 4uM adjacent sections of SCC tissue microarray were separately stained for CYFIP1 and NOTCH1 
(n=286). Immunohistochemical analysis of their expression in human SCC showed similar 
immunoreactivity patterns for both proteins. The expression was concomitantly increased in the 
suprabasal epidermis layers. (b) Statistical analysis of the immunoreactivity showed significant 
correlation of expression between NOTCH1 and CYFIP1 with the r = 0.5; p < 0.0001. (c) SCC13 cells 
were infected with a recombinant retrovirus expressing constitutively active Notch1 together with GFP 
(pincoNotch1), or with a virus overexpressing GFP (pincoGFP) alone followed, 72h later, by mRNA and 
(d) protein expression analysis. Similar results were obtained in three independent experiments. (e) 
SCC13 cells were stably infected with a retroviral vector expressing a flag-tagged activated Notch1 
protein fused to the human estrogen receptor (SCC13Nert), or empty vector control (SCC13Neo). Cells 
were subsequently treated with Tamoxifen at 1.0 uM concentration, collected after 30h and analyzed for 
CYFIP1 and (f) HES1 mRNA and (g) protein expression. Tamoxifen mediated activation of the Notch1 
pathway significantly increased the mRNA and protein levels of both CYFIP1 and HES1 which has 
served as control downstream target.  
 
Further sequence analysis of the proximal region of the human CYFIP1 gene promoter 
revealed the presence of a “canonical” CSL-binding site located at -2.9kb and -0.9kb from the 
transcription start site (TSS) (Figure 3a). To verify NOTCH1 binding to these sites, we 
performed ChIP assays with extracts from human primary keratinocytes under confluent, 
differentiating conditions and from normal human epidermis (Figure 3b and 3c respectively). 
ChIP analysis showed specific binding of the Notch1 protein to both of the predicted motifs 
within the promoter (-2.9 and -0.9 kb position).  
Further functional analysis of the NOTCH1 binding to the CYFIP1 promoter was performed. 
Interestingly the overexpression of functional Notch1 did not increase the luciferase activity 
in the construct with the two putative NOTCH1 binding sites of CYFIP1 promoter (Figure 3d). 
To address the question of the NOTCH1 – CYFIP1 interaction the cyclohexamide protein 
synthesis inhibition assay was performed (Figure 3e). SCC13 NeoNERT cells overexpressing 
Notch1 protein bound to the estrogen receptor were treated with cyclohexamide to block any 
further protein synthesis. With the addition of tamoxifen, preexisting NOTCH1 was activated 
within the NeoNERT cells. This maneuver induced an increase in CYFIP1 mRNA expression, 
proving the direct nature of the binding of Notch1 to the CYFIP1 promoter. 
 
Figure 3. Endogenous Notch1 binds to the CYFIP1 locus within specific regions of chromatin 
organization. 
(a) Schematic illustration of ChIP results: TSS – transcription starting site, CLS-binding motifs are 
represented by the red bars. (b) Human primary keratinocytes and (c) total epidermis extracts of human 
epidermis were processed for ChIP assays using an antibody specific for NOTCH1, utilizing non-
immune IgGs as control. PCR amplification of the various regions of the human CYFIP1 promoter 
encompassed the following CSL-binding sites: -2.9k bp: 5’-GAGGTGGGAACTA-3’; -0.9k bp: 5’-
AATGTGAGAAAGT-3’. Un-precipitated chromatin preparations were similarly analyzed and used as 
“input DNA” control. The nucleotide sequence of the PCR primers is given in the materials and methods. 
The results are representative of two independent experiments. The relative amount of precipitated 
DNA, expressed in arbitrary units, was calculated after normalization for total input chromatin, according 
to the following formula [292]: % total = 2deltaCt x 5 where detaCt = Ct (input) – Ct (immunoprecipitation). 
Ct, cycle threshold. (d) 3 kb CYFIP1 promotor sequence with the two putative NOTCH1 binding sites 
was cloned and used for the luciferase activity assay. Increased luciferase activity was observed in 
response to NOTCH1 overexpression in the positive control (pGA), but not in the cells with the cloned 
CYFIP1 promotor. (e) To address the question of direct CYFIP1 regulation by Notch1 a further 
experiment with the protein synthesis inhibitor – cyclohexamide was used. Briefly, NeoNERT cells 
overexpressing Notch1 protein bound to the estrogen receptor where treated with cycloheximide to block 
any further protein synthesis. With the addition of tamoxifen, preexisting NOTCH1 was activated within 
the NeoNERT cells. This maneuver induced an increase in CYFIP1 mRNA expression, proving the direct 
nature of the binding of Notch1 to the CYFIP1 promoter.  
 
Notch1 regulates cell invasion through CYFIP1 
To verify the differential expression of CYFIP1 between invasive and non-invasive cells, an 
invasion assay using a matrigel coated PET membrane was performed. This assay allows the 
distinction of invasive from non-invasive cells within the population of the SCC13 cell line. Flow 
cytometry showed a different distribution of CYFIP1-positive versus CYFIP1-negative cells in 
these two subpopulations (Figure 4a). Within the non-invasive population, 89.9 % of the cells 
brightly expressed CYFIP1, while only 7.52 % expressed CYFIP1 dimly. Within the invasive 
population, however, most cells showed a dim CYFIP1 expression, while only 23.4 % brightly 
expressed CYFIP1 (p < 0.001).  
To verify Notch1 as a modulator of invasive capacity, SCC13 cells with Tamoxifen-inducible 
NOTCH1 (SCC13Nert) were used in an invasion assay. To assess the interplay between NOTCH1 
activation, CYFIP1 expression and invasion capacity, these cells were treated either with 
Cyfip1-specific siRNA (NertsiCYFIP1) or control siRNA (NertsiCTRL). Cells stably infected with 
empty vector control (SCC13Neo) and treated with CYFIP1-specific siRNA (NeosiCYFIP1) or 
control siRNA (NeosiCTRL) served as control for the Notch1 induction.  Interestingly, the 
induction of Notch1 activity in SCC13 cells dramatically reduced their invasive potential (Figure 
4b and 4c) in parallel to the induced expression of CYFIP1 protein (Figure 4d). This reduced 
invasive phenotype was partially rescued by inhibition of Cyfip1. Induction of NOTCH1 activity 
in the SCC13Nert cells was verified by the induction of p21 expression (Figure 4d). This 
experiment was repeated with two different CYFIP1 specific siRNAs.  
 
Figure 4. NOTCH1 inhibits cell invasion through CYFIP1. 
(a) SCC13 were starved for 2 days and then seeded in the matrigel coated chamber, where the coated 
membrane with 8 um pores separated the cells from the medium full in supplements. The cells were 
then cultured for 22 hours. After this timeframe the cells that migrated through the membrane were 
separated from the remaining cells and thus divided to invasive and non-invasive fraction of SCC13 
cells. The cells were next stained for CYFIP1 and analyzed by FACS. The invasive fraction of SCC13 
cells shows a lower percentage of CYFIP1 positive cells as compared to the non-invasive fraction (p < 
0.001). (b) SCC13 cells were stably infected with a retroviral vector expressing a flag-tagged activated 
NOTCH1 protein fused to the human estrogen receptor (SCC13Nert), or empty vector control 
(SCC13Neo). The cells were subsequently treated with siRNA targeting CYFIP1 mRNA of unspecific 
control. The cells were next kept in starving conditions, seeded on the matrigel coated membrane with 
8 um pores and treated with Tamoxifen. After 22h hours of incubation the invasive and non-invasive 
cells were counted and the invasion capacity was calculated as indicated in the manufacturer protocol. 
Section (b) represents the density of the invasive populations in the end of the experiment. (c) SCC13 
with activated NOTCH1 and treated with control siRNA (Nert siCtrl) showed drastically decreased 
invasive capacity, which could be partially restored when the Notch1 activated SCC13 cells were treated 
with CYFIP1 specific siRNA (Nert siCYFIP1). (d) For control, the cells were parallel analyzed for CYFIP1 
and p21 expression.   
  
6.2.4 Discussion 
The pro-differentiation and tumor suppressive functions of Notch signaling in keratinocytes 
are well established [283]. However, little is known about its mechanism. It has previously 
been shown that Notch activation is involved in in the cell-cycle control of keratinocytes via 
p21WAF1/Cip1 [293]. Notch activation also induces differentiation of these cells through a more 
indirect mechanism, involving modulation of integrin expression in the basal layer, of p63 as 
well as of IRF family members [72, 287]. We show here that Notch signaling is also involved in 
the regulation of keratinocyte invasive potential through the modulation of CYFIP1 expression.  
To date, CYFIP1 has been shown to inhibit tumor cell invasion in models of colon, lung and 
breast cancers [147]. It has been demonstrated that in these three particular tumors, its 
expression is decreased compared to corresponding normal tissues. In our study, CYFIP1 
expression was decreased at both the mRNA and protein level in in-situ and invasive SCC when 
compared to normal skin. Interestingly, progression of in-situ to invasive SCC was associated 
with a progressive downregulation of CYFIP1 expression, suggesting a function for CYFIP1 as 
an invasion inhibitor in SCC similar to that reported for other tumors. The histological 
differentiation of SCC is inversely linked to recurrence, invasion, and metastasis [37, 127, 280-
282, 294]. Thus, poorly and undifferentiated SCC have the highest rate of invasion and 
metastasis, while moderately differentiated SCC were shown to have a higher rate of invasion 
and metastasis. Our analysis of CYFIP1 expression in well-, moderately- and poorly-
differentiated squamous cell carcinomas showed down-regulated CYFIP1 expression in line 
with a loss of differentiation in tumor cells, suggesting a possible mechanism linking the loss 
of histological differentiation to increased invasive potential, a phenomenon observed also in 
other tumors such as esophagus, prostate, colon and breast [125, 295-298]. 
We show here that CYFIP1 gene transcription is induced in differentiating keratinocytes by a 
Notch-dependent mechanism. Activation of Notch1 signaling, either directly by 
overexpression of an active Notch1 variant, or through a conditional manipulation, both 
increased CYFIP1 mRNA and protein expression in cells. We further confirmed the binding of 
activated NOTCH1 to the CYFIP1 promoter within specific CSL-binding sites, revealing CYFIP1 
as a direct NOTCH1 target. This binding was not confirmed by the luciferase assay, but further 
analysis with the cyclohexamide protein synthesis inhibition assay proved the direct nature of 
the binding of NOTCH1 to the CYFIP1 promotor. We also observed decreased levels of CYFIP1 
expression in SCC12 and SCC13 cell lines compared to normal human keratinocytes. This 
decrease can be explained by compromised Notch signaling in these cells [239, 299]. These 
results explain the observed correlation in the expression of Cyfip1 and NOTCH1 in the SCC 
tumors.  Both CYFIP1 and NOTCH1 were relatively weakly expressed in the basal layer of the 
epidermis, which forms the leading front of the tumors. Both CYFIP1 and NOTCH1, however, 
were upregulated in keratinocytes of the spinous and granular layer, e.g. in cells with 
increasing differentiation.   
CYFIP1 expression has been negatively correlated with the invasion of malignant cells in lung, 
colon, breast and bladder tumors. We assessed whether these phenomena apply to cutaneous 
SCC as well. To distinguish migration from invasion, SCC13 keratinocytes were cultured on a 
matrigel-coated membrane. Under the starving conditions and chemotactic stimuli, 
keratinocytes are forced to inhibit differentiation and move in the direction of the attractant 
[300]. In line with the reported role of invasion suppressor for CYFIP1, the invasive fraction of 
SCC13 cells down-regulated their CYFIP1 expression. Our results go along with the results of 
Silva and colleagues [147] where they also performed an in vivo assay where SCC cells with 
reduced CYFIP1 expression showed drastically increased invasive properties 
Since CYFIP1 is regulated by Notch signaling and plays the role in cancer cell invasion, the 
remaining question was if increased Notch signaling may influence this process as well. Our 
results revealed a drastic decrease in the invasion of SCC cells upon activation of the NOTCH1 
signaling pathway. This occurred in parallel with increased CYFIP1 expression. Interestingly, 
however, the inhibition of CYFIP1 expression in Notch-activated cells partially rescued the 
invasive capacity of the SCC cells. These results shed new light on the function of Notch 
signaling by suggesting NOTCH1 to function as a promoter of differentiation and an inhibitor 
of invasion. The Notch1 mediated inhibition of invasion may be partially regulated by the 
NOTCH1 mediated induction of CYFIP1 expression.  Our data are of likely clinical significance, 
because they suggest a mechanism for the observed correlation between the loss of tumor 
differentiation and increased destructive and invasive growth.  
 
 
  
7. Discussion 
 
The last chapter discusses the key finding of my PhD research work, puts them into a broader 
perspective and provides an outlook on possible future therapies. For more specific 
discussions dealing with the single projects please refer to the corresponding manuscripts in 
the results section. 
 
 
Within the last decades SCC incidence has been constantly rising making SCC the second most 
common human skin cancer within the Caucasian population. Recent estimates on the show 
that about 2.1% of patients suffering from invasive SCC in the United States die [301]. 
Importantly, SCC does not necessary arise form KIN III AK, but has been shown to directly 
develop from KIN I and KIN II lesions as well. Since the cancer and its precursor lesions arise 
from body parts chronically exposed to solar UV light, sun protection is advised. Although, 
awareness of the danger posed by excessive UV exposure is generally given nowadays, the 
time lag between cutaneous sun damage and the consecutive SCC formation still results in 
increasing numbers of SCC cases. Due to the continuous intake of immunosuppressive drugs, 
OTR patients have a dramatically increased risk of developing SCC. Since the immune system 
plays a vital role in clearing critically UV damaged keratinocytes and therefore preventing SCC 
formation, OTR patients need continuous sun protection in the form of adequate clothing and 
high protection factor sun screen. Routinely, Invasive SCC is surgically excised without further 
ado. For AK and earlier stages of SCC there is a variety of topical treatments available which 
do result in reliable cancer clearance but induce disfiguring scaring through induction of 
inflammation and severe tissue damage. There is a high demand for alternative treatment 
strategies with potent inhibitory effects on cancer proliferation without causing excessive 
inflammation and leading to improved cosmetic outcomes. 
 
In 1993 Ambros and colleagues discovered a novel non-coding class of small RNAs in C. 
elegans. Soon after, a huge research interest evolved around the newly discovered RNA 
molecules leading to the discovery of more and more miRNAs in various species including 
humans [302]. In the subsequent years researches were gradually understanding the impact 
of their findings on molecular Biology. It became evident that most of the genes are regulated 
by miRNAs and that flaws within this complex network are associated with disease and even 
cancer. 
Due to imperfect matching of the miRNA-mRNA complex, a miRNA typically targets many 
mRNAs and vice versa. Furthermore, the different expression levels of miRNAs and matching 
mRNAs between cells result in individual miRNA-mRNA target interactions with astonishing 
consequences. The depletion of a miRNA could lead to a cell cycle arrest in one tissue while it 
may induce uncontrolled proliferation in another [303, 304]. Although miRNA targets should 
be easily to predict by taking the rules of Watson-Crick into account, the actual situation is 
very different making context specific target identification and functional investigation 
inevitable [305]. 
Up to date, little is known about miRNAs in SCC. 
 
A large microarray scan, performed by our collaboration partners in Lausanne, revealed a 
highly disturbed miRNA pattern in SCC. This circumstance is generally observed in cancer and 
was initially identified in B-cell chronic lymphocytic leukemia (CLL) [306]. Subsequent findings 
in patients with breast, lung, ovarian and cervical cancers underline the general prevalence of 
this phenomenon [307-309]. 
Among the miRNAs with low abundancy in SCC, miR-181a caught our attention due to its 
highly reproducible and even downregulation among patient samples (n=14) and most SCC 
cell lines. miR-181a seems to be affected in many cancers, such as ovarian, breast and colon 
cancer, suggesting devastating consequences of miR-181a deregulation in human organs. 
Indeed, miR-181a is not only a consequence of the chaotic transcriptome situation in cancer 
but a causative factor playing effective roles in the progression of these malignancies [258, 
310]. 
The high context specificity, described above, seems to be particularly true for miR-181a [201]. 
The main body of cancer related miR-181a publications characterizes it as an oncomir with 
tumor promoting effects on cellular invasion and formation of metastasis. In a smaller subset 
of these studies miR-181a incudes cancerous proliferation, as demonstrated in gastric cancer 
[251]. Interestingly, miR-181a exhibits a tumor suppressive role in another subset of 
malignancies with consequences to various cancer hallmarks [256-259]. Along these lines, 
there is evidence form two studies suggesting that miR-181a may even overdue its anti-
proliferative role, inducing autoimmunity, specifically systemic lupus erythematosus [311, 
312]. Our results showed that modulation of miR-181a in SCC cells negatively correlated with 
cellular proliferation rates, making miR-181a a tumor suppressor in the context of 
keratinocyte carcinogenesis. mir-181a overexpression almost arrested SCC proliferation 
accompanied with induction of apoptosis, resulting in values down to 20% compared to the 
negative controls in our in vitro and in vivo experiments. miR-181a downregulation, on the 
other hand, accelerated proliferation in normal keratinocytes to an average of 150% 
accompanied with hyperkeratosis and parakeratoses, mimicking cancerous keratinocyte 
behavior. Showing functionality beyond epithelial cancers, miR181a overexpression 
suppresses cell growth in xenograft tumors in chronic myelogenous leukemia [27] and large 
B-cell lymphoma [28]. The effect size on SCC in our study seemed larger, suggesting 
therapeutic potential for miR-181a against SCC. Indeed, there is hope for patients suffering 
from skin diseases that they may profit from enormous efforts currently being undertaken to 
establish miRNA modulation as effective treatment any time soon. While most of the 
approaches focus on central organs, such as the heart, lung or liver, Guinea-Viniegra and 
colleagues successfully treated psoriasis by cutaneous application of miR-21 inhibitors in a 
mouse model [313]. 
Based on dual luciferase experiments performed in the context NSCLC, ovarian cancer and 
head and neck SCC, we chose to evaluate the impact of direct miR-181a - KRAS interaction in 
SCC [248, 259, 263].  Therefore, we modified the classical dual luciferase reporter assay using 
functional KRAS protein as a readout which simultaneously added another dimension to the 
approach.  This system allowed us to perceive the miR-181a-KRAS interaction above the 
background of endogenous KRAS expression. We thus supported the previously found 
interaction between miR-181a and KRAS 3’UTR and directly linked its main functional 
consequence to SCC – increased cellular viability. Despite being the most frequently mutated 
oncogene in human cancer [314], little is known about KRAS’ oncogenic significance in SCC so 
far. KRAS hyperactivity, caused by activating mutations as well as faulty posttranscriptional 
control, has been identified as a main tumor driver in cancers of the colon, pancreas and lung 
mainly mediated by MAPK signaling [92, 264, 266]. Our findings confirmed that the oncogenic 
axis of KRAS ‐ RAF–MEK–ERK is controlled post-transcriptionally by miR-181a and may be 
critical in SCC development. Unsuccessful attempts in directly targeting Ras family members, 
by the use of small molecule inhibitors in the past, have characterized small GTPases as 
undruggable. Although, latest efforts in chemical structure determination reignited 
researcher’s hope, it will be a long and tedious way to a reliably functioning Ras inhibitor [314, 
315]. Alternatively, miR-181a mimics could be adopted to tame KRAS’ oncogenic features, at 
least in order to bridge the present times where no small molecule inhibitors are available. 
Keratinocyte differentiation is a well-studied process in which the cells mature and eventually 
die. Along these lines, keratinocytes protect themselves from becoming cancerous by entering 
the differentiation cascade preponed. Exposure to carcinogenic factors like UV irradiation is a 
typical trigger for example [19]. During the keratinocyte differentiation process many tumor 
suppressive pathways are activated, leading to gradual metabolic shutdown and eventually to 
cell death [20]. Hence, keratinocyte differentiation is considered as a potential tumor-
suppressive mechanism. Our data showed that differentiation in keratinocytes at large 
increases miR-181a expression, suggesting a role for miR-181a in a common pathway of 
differentiation, and that removing miR-181a is critical for the transition of keratinocytes into 
SCC. A similar weight has been reported in keratinocytes for miR-203 and miR-24 [40-42], 
underlining the impact of miRNAs in cellular differentiation [43-45]. We thus believe that miR-
181a is an important mediator of differentiation in keratinocytes. 
 
The highly conserved cell surface receptor Notch1 is known to initiate expression of various 
gene profiles, playing vital roles during human embryonic development and homeostasis of 
the adult body. Among Dermatologists NOTCH1 is mainly known as a key trigger of 
keratinocytes differentiation and tumor suppression [283, 284, 316]. The exact mechanisms, 
however, are only sketchily understood. One piece was added to the puzzle by research 
performed in Gian-Paolo Dotto’s lab where p21WAF1/Cip1 was identified as a key mediator for 
Notch1 induced keratinocyte growth arrest [283]. More evidence underlining NOTCH1‘s 
tumor suppressive role in keratinocytes was gathered by Proweller and Colleagues by 
constructing an in vivo mouse model expressing a dominant negative form of Notch1. As a 
result, these mice spontaneously developed SCC-like lesions on multiple body sites associated 
with Wnt/β-catenin accumulation in the nucleus [317]. In our recent study, we propose a 
novel mechanism of how NOTCH1 suppresses another cancer hallmark – invasive potential, 
through CYFIP1 upregulation.  
In concert with a multi protein complex CYFIP1 is known as a negative regulator of Arp2/3 
induced actin remodeling, which is fundamental for keratinocyte migration and invasion [147, 
318]. In models of colon, lung and breast cancers CYFIP1 expression was decreased compared 
to the according normal tissues and thus no longer able to inhibit cellular invasion [147]. 
Furthermore, histological data accessible via the “Human protein Atlas” reveals weak to 
moderate CYFIP1 positivity in the majority of invasive cancers 
(http://www.proteinatlas.org/ENSG00000273749-CYFIP1/cancer, 2016-11-11) [319, 320]. In 
order to shed light on the CYFIP1 situation in SCC, we conducted a comprehensive study, 
composed out of 286 SCC samples and corresponding normal skin. In accordance to the 
majority of other malignancies, CYFIP1 expression was decreased at both mRNA and protein 
level in in-situ and invasive SCC when compared to normal skin. Furthermore, progression of 
in-situ to invasive SCC was associated with a progressive decline of CYFIP1 histological 
positivity, suggesting a function for CYFIP1 as an invasion inhibitor in SCC similar to that 
reported for other tumors [147]. Interestingly, we observed a correlation with the samples’ 
differentiation state and CYFIP1 presence. Numerous studies describe histological 
differentiation of SCC as being inversely linked to recurrence, invasion, and metastasis [4, 5, 
7-9, 33][37, 127, 280-282, 294]. Well-, moderately- and poorly-differentiated squamous cell 
carcinomas showed decreased CYFIP1 positivity in line with a loss of differentiation in tumor 
cells, suggesting a possible mechanism linking the loss of histological differentiation to 
increased invasive potential. A similar phenomenon was observed in tumors of the esophagus, 
prostate, colon and breast [125, 295-298]. 
In our study we report a mechanism in which Notch1 directly induced CYFIP1 expression in 
differentiating keratinocytes. We achieved endogenous NOTCH1 activation by culturing 
primary keratinocytes in a confluent state for prolonged times up to a week. The feasibility of 
this simple method is well known whereas successfully activated cells enter the differentiation 
cascade [60, 293, 321]. Alternatively, we artificially overexpressed NOTCH1 in keratinocytes 
using different, well established, plasmid constructs [321, 322]. In either way, Notch1 
expression correlated with CYFIP1 expression on mRNA as well as on protein level. Along these 
lines we observed decreased levels of CYFIP1 expression in SCC12 and SCC13 cell lines 
compared to normal human keratinocytes. This decline can be explained by jammed Notch 
signaling in these cells [239, 299]. Furthermore, we were able to confirm direct interaction of 
NOTCH1 DNA interacting domain CSL with a putative CYFIP1 promotor region via ChIP assay. 
For unknown reasons an actual transcription as a result of CLS binding to the CYFIP1 promotor 
could not been observed via dual luciferase reporter assay. By choosing a cyclohexamide 
protein synthesis inhibition assay instead, we were able to prove the direct nature of the 
binding of Notch1 to the CYFIP1 promotor finally. 
 
A negative regulatory role suppressing malignant invasion has been ascribed to CYFIP1, 
showing functionality in lung, colon, breast and bladder cancers [147]. We assessed whether 
this phenomenon applies to cutaneous SCC as well. 
Another firm hint towards CYFIP1 functionality as a negative regulator of cellular invasion was 
obtained by histological analysis of invasive SCC and normal human skin. Both CYFIP1 and 
NOTCH1, were strongly expressed in keratinocytes of the spinous and granular layer, e.g. in 
cells with increasing differentiation. CYFIP1 and NOTCH1 protein, however, were hardly 
detectable in the basal epidermal layer, which forms the leading front of invasive tumors. 
Similar conclusions were drawn by histological observation of other invasive organ cancers 
[147]. 
To distinguish migration from invasion in an in vitro assay, SCC13 keratinocytes were cultured 
on a matrigel-coated membrane under serum starvation. FBS on the opposite side of the 
membrane forced them to inhibit differentiation and invade through the collagen gel layer 
[300]. Subsequent FACS analyses revealed lower CYFIP1 levels of the invading cell fraction 
compared to the non-invasive part resting in the collagen layer. Silva and colleagues came to 
the same conclusion when performing an in vivo invasion assay where SCC cells with reduced 
CYFIP1 expression showed drastically increased invasive behavior [147]. 
Having demonstrated that low levels of NOTCH1 an CYFIP1 are not only histologically 
associated with SCC but do functionally potentiate SCC invasiveness, the remaining question 
was whether this effect could be reverted by activating NOTCH1 and the subsequent cascade. 
In another in vitro invasion assay, we stably overexpressed NOTCH1 in SCC13 cells leading to 
CYFIP1 expression accompanied by a complete abrogation of invasion. siRNA mediated CYFIP1 
knock down rescued the invasive nature of SCC13 cells. The effect size of NOTCH1 induced 
abrogation of cellular invasion, suggests the Arp2/3 complex as a promising therapeutic target 
against invasive SCC. This speculation is supported by a comprehensive study in highly invasive 
pancreatic cancer, where Arp2/3 silencing tamed the cancers aggressive behavior [323]. 
To our knowledge, we are the first to report a functional mechanism connecting NOTCH1 
induced keratinocyte differentiation with CYFIP1 mediated inhibition of SCC invasion. These 
finding will shed new light on evaluating SCC differentiation status for diagnostic and 
prognostic purposes.  
 
Overall the current PhD thesis contributes to a better understanding of the molecular 
mechanisms underlying critical SCC proliferation and invasion. Specific key players within this 
network, elaborated in our studies, may serve as potential starting points for novel SCC 
treatments. Together with our collaboration partners, we are currently investigating miRNAs 
and other factors specific to OTR. Our goal is to come up with new insights and treatment 
options against the SCC burden of these patients. 
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9. Abbreviations 
 
 
5-FU     5-Fluorouracil 
80H-G     guanine to 8-hydroxyguanine 
AK     Actinic keratosis 
Ago     Argonaute 
Arp2/3     Actin related protein2/3 complex 
ATF3     Activating transcription factor 3 
Blas     Blasticidin 
BSA     Bovine serum albumin 
BrdU     Bromodeoxyuridine 
CD     Cluster of differentiation 
CDKN2A    Cyclin-dependent kinase inhibitor 2A 
C.elegans    Caenorhabditis elegans 
ChIP     Chromatin Immunoprecipitation assay 
CLL     Chronic lymphocytic leukemia 
CLSM     Confocal laser scanning microscope 
COX-2     Ccyclooxygenase-2 
CsA     Cyclosporine A 
CYFIP1     Cytoplasmic FMR1 interacting protein 1 
DMEM     Dulbecco´s modified eagle medium 
DNA     Desoxyribonucleic acid 
Dox     Doxycycline 
ECL     Enhanced chemiluminescence 
ECM     Extracellular matrix 
EMT     Epithelial to mesenchymal transition 
ERK     Extracellular regulated MAP kinase 
FBS     Fetal bovine serum 
FCS     Fetal calf serum 
GAP     GTPase activating proteins 
GDT     Guanosine diphosphate 
GEF     GTP-exchange factor 
GTP     Guanosine triphosphate 
h     Hour 
HCl     Hydrochloric acid 
H&E     Hematoxylin and eosin 
HIV     Human immune deficiency virus 
HKS     normal human keratinocytes 
HNSCC     Head and neck squamous cell carcinoma 
HRAS     Harvey rat sarcoma viral oncogene homolog 
IgG     Immunoglobulin G 
IL     Interleukin 
IL13RA2    Interleukin-13 receptor alpha 2 
IL1R2     Interleukin-1 receptor 2 
IM     Ingenol mebutate 
JNK     Jun amino-terminal kinase 
KIN     Keratinocyte intraepidermal neoplasia 
KRAS     V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
MAPK     Mitogen-activated protein kinase 
min     Minutes 
miRNA     microRNA 
miR-181a    microRNA-181a 
mTOR     Mechanistic Target of Rapamycin 
NFAT     Nuclear factor of activated T cells 
NRAS     Neuroblastoma RAS viral oncogene homolog 
NRF2     Nuclear factor erythroid 2-related factor 2 
NSCLC     Non-small cell lung carcinoma 
ORF     Open reading frame 
OTR     Organ transplant recipient 
P-Bodies    Processing bodies 
PBS     Phosphate-buffered saline 
PCR     polymerase chain reaction 
PDT     Photodynamic therapy 
PKC     Protein kinase C 
PMSF     Phenylmethylsulfonylfluorid 
Puro     Puromycin 
RAF     v-Raf murine sarcoma viral oncogene homolog 
RISC     RNA induced silencing complex 
RNA     Ribonucleic acid 
ROS     Reactive oxygen species 
RT     Room temperature 
RTK     Receptor tyrosine kinase 
SD     Standard deviation 
SDS     Sodium dodecyl sulfate 
sec     Seconds 
SEM     Standard error of the mean 
snRNA     Small nuclear RNA 
SPF     Sun protection factor 
TBS     Tris-buffered saline 
TERT     Telomerase reverse transcriptase 
TGFβ     Transforming growth factor β 
TLR     Toll-like receptor 
USZ     University Hospital Zurich 
UTR     Untranslated region 
UV     Ultra-violet 
WASP     Wiskott–Aldrich syndrome protein 
WAVE     WASP family verprolin-homologous 
WB     Western blot 
Wt     Wild-type 
XP     Xeroderma pigmentosum 
  
10. Acknowledgments 
 
I would like to thank all my friends, colleagues and family for sharing many good and fun 
moments over the last years! Especially I would like to thank: 
 
My boss Günther Hofbauer for giving me the opportunity to work in his Laboratory on great 
projects.  You have been an excellent supervisor, giving me a high degree of trust and freedom 
in pursuing my scientific work. Especially, I would like to thank you for all the coaching and 
mentoring to successfully implement my future career plans - it helped a lot! 
 
My former supervisors, Winfried Wunderlich and Lukas Huber, for keeping in touch and for 
valuable research inputs. Without your excellent coaching during my study time, I would 
probably not have made it to Zürich at all. 
 
Piotr Dziunycz for introducing me to the lab work in the Dermatology Department and for 
laying the foundations for my PhD projects. You became one of my best friends over the last 
years. 
 
Our long term collaboration partner, Gian-Paolo Dotto and his team, for interesting research 
opportunities, fruitful discussions and valuable input for my own research during our lab visits 
in Lausanne. 
 
My close Collaboration partners Martin Falke and Rémy Denzler for realizing our most 
venturous experiments. 
 
Onur Boyman, Jan Krützfeldt and Gian-Paolo Dotto for being dedicated Committee members 
and for giving me direction as well as valuable advice during our annual meetings. 
 
Dr. Robert Gniadecki for critically reviewing my Thesis and for his valuable input.  
 
Former and current colleagues of our group: Guillaume “Monsieur de la Roux”, Guergana 
Iotzova-Weiss, Sandra Freiberger, Qinxiu Liu, Alex Kuzmanov, Paola Atzei and Naomi Bollag. 
Thank you for the great working atmosphere. 
 
All the nice Medical Doctors from F2, friends from Gloriastrasse, and the Schliern-Crew for the 
good times we had. Special Thanks goes to Deepa Mohanan, Jil Dreier, Phil Cheng, Jan Käsler, 
Daniel Hug and Monika Hakerud for helping me maintain my life-work balance and sharing 
many good and fun moments. You were truly important in keeping me motivated and sane 
over the years of my Thesis. 
 
Friends and Colleagues from the Cancer Network Zürich for all the good times we had during 
nights out in the City and during Student’s Retreats. 
 
Colleagues from the Dermatology Department, especially Steve Pascolo for numerous fruitful 
discussions, the Biobank team for taking care of patient samples and Ines Kleiber-Schaaf for 
her help with histology preparations. 
 
My special Thanks goes to my parents, my brother and Madleen for supporting and 
encouraging me during the ups and downs of all the years. 
  
11. Curriculum Vitae 
 
 
MSc Johannes NEU 
Date of birth: 11.11. 1985 
Nationality: Austrian 
 
Education 
 
2013 - present Doctoral Studies in Tumor Biology 
 Department of Dermatology, University Hospital Zürich, Switzerland 
  
2012 Master Thesis “Analysis of a novel MAPKplus Inhibitor in comparison 
to specific MEK Inhibitors” 
 Division for Cellular Biology – Biocenter Innsbruck 
 Medical University of Innsbruck, Austria 
 
2010 - 2012 Master’s Studies in Molecular Cell- and Developmental Biology 
 Leopold Franzens University Innsbruck, Austria 
 Graduation date: 6.12. 2012 
 
2009 Bachelor Thesis “The Nervous System of Macrostomum lignano” 
 Department of Zoology 
 Leopold Franzens University Innsbruck, Austria 
 
2008 - 2010 Bachelor’s Studies in Chemistry 
 Leopold Franzens University Innsbruck, Austria 
 
2006 - 2009 Bachelor’s Studies in Biology 
 Leopold Franzens University Innsbruck, Austria 
 Graduation date: 16.3. 2010 
 
1996 - 2004 Secondary School, Bundesgymnasium Sillgasse, 
 Innsbruck, Austria 
 Matura: 2014 
 
 
Scholarships and Programs 
 
2013 - present Cancer Biology PhD Program of the Life Science Zurich Graduate 
School University of Zurich / ETH Zurich, Switzerland 
  
2013 Hartmann Müller - Stiftung für medizinische Forschung. CHF 27'023.  
 
 
Publications and Posters 
 
Publications: 
- Freiberger SN, Cheng PF, Neu J et al. Ingenol Mebutate Signals via PKC/MEK/ERK in 
Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Mol Cancer 
Ther. 2015 Sep;14(9) 
 
- Dziunycz PJ, Lefort K, Neu J et al. The oncogene ATF3 is potentiated by cyclosporine A 
and ultraviolet light A. J Invest Dermatol. 2014 Jul;134(7) 
 
- Schnaiter S, Fürst B, Neu J et al. Screening for MAPK modulators using an in-cell 
western assay. Methods Mol Biol. 2014;1120:121-9. 
 
Posters: 
- Neu J. NIPT – Non-invasive prenatal testing. A lucrative application for Next Generation 
Sequencing. International Summer School in Aarhus, Denmark. 2016 
 
- Neu J, Dziunycz P, Lefort K et al. The role of miR-181a in cutaneous squamous cell 
carcinoma. 44th ESDR meeting in Copenhagen. 2014. 
 
Professional Membership 
2013 - 2015  European Society of Dermatological Research (ESDR) 
